

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	599	(544/158).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/03/13 09:28
L2	214	(514/239.2).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/03/13 09:26
L3	3	((("4956388") or ("5023269")).PN.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/03/13 09:28

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	FEB 26	MEDLINE reloaded with enhancements
NEWS	31	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:16:01 ON 13 MAR 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 08:17:03 ON 13 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3

DICTIONARY FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10524798.str



chain nodes :

8 9 24 25 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22

chain bonds :

2-26 2-27 3-28 3-29 5-24 5-30 6-25 6-8 8-17 8-9 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 17-18
17-22 18-19 19-20 20-21 21-22

exact/norm bonds :

1-2 1-6 2-3 2-26 2-27 3-4 3-28 3-29 4-5 5-6 5-24 5-30 6-25 8-9 9-11

exact bonds :

6-8 8-17

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22

isolated ring systems :

containing 1 : 11 : 17 :

G1:O,S

G2:C,H

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,S

G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:17:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 75 TO ITERATE

100.0% PROCESSED 75 ITERATIONS

38 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 981 TO 2019

PROJECTED ANSWERS: 391 TO 1129

L2 38 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 08:17:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1631 TO ITERATE

100.0% PROCESSED 1631 ITERATIONS

851 ANSWERS

SEARCH TIME: 00.00.01

L3 851 SEA SSS FUL L1

=> s l3 and caplus/lc

53707523 CAPLUS/LC

L4 738 L3 AND CAPLUS/LC

=> s l3 not l4

L5 113 L3 NOT L4

=> d 15 ed<2003
'ED<2003' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> s 15 ed<2003
MISSING OPERATOR

=> d his

(FILE 'HOME' ENTERED AT 08:16:01 ON 13 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:17:03 ON 13 MAR 2007

L1 STRUCTURE UPLOADED
L2 38 S L1
L3 851 S L1 FULL
L4 738 S L3 AND CAPLUS/LC
L5 113 S L3 NOT L4

=> s 15 and ed>2003
 29305412 ED>2003
 (ED>20039999)


L6 112 L5 AND ED>2003

=> s 15 not 16
L7 1 L5 NOT L6

=> d 15 112-113


L5 ANSWER 112 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 695815-31-7 REGISTRY
 ED Entered STN: 18 Jun 2004
 CN Morpholine, 2-[(R)-(3-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, (2R)-
 (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H20 F N O2 S
 CI COM
 SR CA

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 113 OF 113 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 135020-15-4 REGISTRY
 ED Entered STN: 19 Jul 1991
 CN Morpholine-3-14C, 6-[(2-ethoxyphenoxy)phenylmethyl]- (9CI) (CA INDEX
 NAME)
 MF C19 H23 N O3
 CI COM
 SR CA



=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10524798.str



chain nodes :

8 9 24 25 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22

chain bonds :

2-26 2-27 3-28 3-29 5-24 5-30 6-25 6-8 8-17 8-9 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 17-18

17-22 18-19 19-20 20-21 21-22

exact/norm bonds :

1-2 1-6 2-3 2-26 2-27 3-4 3-28 3-29 4-5 5-6 5-24 5-30 6-25 8-9 9-11

exact bonds :

6-8 8-17

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22

isolated ring systems :

containing 1 : 11 : 17 :

G1:O,S

G2:C,H

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS

L8 STRUCTURE UPLOADED

=> d

L8 HAS NO ANSWERS

L8 STR



G1 O,S

G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l8

SAMPLE SEARCH INITIATED 08:20:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s l8 full

FULL SEARCH INITIATED 08:20:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 30 TO ITERATE

100.0% PROCESSED 30 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L10 1 SEA SSS FUL L8

=> s l10 and caplus/lc
53707523 CAPLUS/LC

L11 1 L10 AND CAPLUS/LC

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

364.75

365.17

FILE 'CAPLUS' ENTERED AT 08:20:32 ON 13 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Mar 2007 VOL 146 ISS 12

FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 08:16:01 ON 13 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:17:03 ON 13 MAR 2007

L1 STRUCTURE UPLOADED

L2 38 S L1

L3 851 S L1 FULL

L4 738 S L3 AND CAPLUS/LC

L5 113 S L3 NOT L4

L6 112 S L5 AND ED>2003

L7 1 S L5 NOT L6

L8 STRUCTURE UPLOADED

L9 0 S L8

L10 1 S L8 FULL

L11 1 S L10 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 08:20:32 ON 13 MAR 2007

=> s l11

L12 1 L11

=> d ibib abs hitstr

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2005:238689 CAPLUS
DOCUMENT NUMBER: 142:291424

TITLE: Method for treatment of depression and anxiety disorders by combination therapy
INVENTOR(S): Arneric, Stephen P.; Clardy, Cathryn M.; Feltner, Douglas; Harrison, Wilma M.; Kavoussi, Richard J.; Pande, Atul C.; Taylor, Charles Price

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 38 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005059654	A1	20050317	US 2004-935826	20040908
AU 2004271796	A1	20050324	AU 2004-271796	20040830
CA 2538412	A1	20050324	CA 2004-2538412	20040830
WO 2005025563	A1	20050324	WO 2004-IB2818	20040830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1675582	A1	20060705	EP 2004-744329	20040830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004014347	A	20061107	BR 2004-14347	20040830
CN 1878546	A	20061213	CN 2004-80033396	20040830
JP 2007505095	T	20070308	JP 2006-525916	20040830
NO 2006001550	A	20060405	NO 2006-1550	20060405
PRIORITY APPLN. INFO.:			US 2003-502304P	P 20030912
			WO 2004-IB2818	W 20040830

OTHER SOURCE(S): MARPAT 142:291424

AB A method is provided of treating depression in mammals, including a human, as well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal in effective amount a combination of active ingredients comprising (a) an alpha-2delta (A2D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and, active agents selected from: (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective noradrenaline re-uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixts. of (b) and (c). A pharmaceutical composition

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
comprising a therapeutically effective amt. (a) an A2D ligand or a

prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from: (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c)


an SNRI or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixts. of (b) and (c) is also provided. Preferred active ingredients for the treatment and the pharmaceutical compn. include pregabalin, gabapentin, sertraline and reboxetine.

IT 847832-28-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of depression and anxiety disorders by combination therapy)

RN 847832-28-4 CAPLUS

CN Morpholine, 3-[(2-ethoxyphenoxy)phenylmethyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 08:16:01 ON 13 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:17:03 ON 13 MAR 2007

L1 STRUCTURE UPLOADED
L2 38 S L1
L3 851 S L1 FULL
L4 738 S L3 AND CAPLUS/LC
L5 113 S L3 NOT L4
L6 112 S L5 AND ED>2003
L7 1 S L5 NOT L6
L8 STRUCTURE UPLOADED
L9 0 S L8
L10 1 S L8 FULL
L11 1 S L10 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 08:20:32 ON 13 MAR 2007

L12 1 S L11

=> s l4

L13 450 L4

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.68	371.85

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.78	-0.78

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 08:22:26 ON 13 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3

DICTIONARY FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s l4 and 1/N

5364956 1/N

L14 703 L4 AND 1/N

=> s l14 and 1-6/S


8828697 1-6/S

L15 142 L14 AND 1-6/S

=> d scan

L15 142 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Morpholine, 4-({(1R)-1-phenylethyl}-2-[(R)-phenyl[2-
(trifluoromethyl)phenyl]thio]methyl)-, (2R)- (9CI)
MF C26 H26 F3 N O S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
10.80	382.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.78

FILE 'CAPLUS' ENTERED AT 08:23:24 ON 13 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l15
L16 42 L15

=> d ibib abs hitstr 1-42

L16 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1144030 CAPLUS
DOCUMENT NUMBER: 145:495549
TITLE: Method and medicinal composition for curing neurasthenia and somatoform disorder.
INVENTOR(S): Liu, Ping; Yu, Duo; Long, Haizhen; Li, Jintong; Li, Hua; Wang, Yu; Dai, Chengxiang; Chen, Guangliang; Xing, Houxun; Xu, Xiping
PATENT ASSIGNEE(S): Beijing Mafo Biomedical Research Center, Inc., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 21pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1850271	A	20061025	CN 2005-10064783	20050422

PRIORITY APPLN. INFO.: CN 2005-10064783 20050422

AB The medicinal composition for curing neurasthenia and somatoform disorder comprises medicinal dosage selective norepinephrine reuptake inhibitor (NARI) or its medicinal salts, and medicinal dosage selective serotonin (or 5-hydroxytryptamine) reuptake inhibitor (SSRI) or its medicinal acceptable salt composition. The NARI comprises tomoxetine, reboxetine, bupropion, imipramine, desipramine, amitriptyline, nortriptyline, maprotiline and protriptyline, and reboxetine methane sulfonate. The SSRI comprises fluoxetine, sertraline, citalopram, paroxetine, fluvoxamine, sertraline hydrochloride, citalopram hydrobromide. The medicinal composition is prepared into oral preparation, i.v. injection or suppository. The somatoform disorder comprises somatoform disorder, hypochondria, somatoform autonomic dysfunction, persistent somatoform pain disorder.

IT 98769-84-7, Reboxetine mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and medicinal composition for curing neurasthenia and somatoform disorder)


RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-[2-ethoxyphenoxy]phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.

L16 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S



L16 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:804431 CAPLUS
DOCUMENT NUMBER: 145:195977
TITLE: A highly sensitive spectrofluorometric method for the determination of a new antidepressant drug, reboxetine, in tablets
AUTHOR(S): Onal, Arman
CORPORATE SOURCE: Faculty of Pharmacy, Department of Analytical Chemistry, Istanbul University, Istanbul, 34116, Turk.
SOURCE: Journal of AOAC International (2006), 89(4), 972-975
CODEN: JAINEE; ISSN: 1060-3271
PUBLISHER: AOAC International
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A highly sensitive, selective, and rapid spectrofluorometric method was developed for the determination of reboxetine (REB) in tablets. The method is based on derivatization with 7-chloro-4-nitrobenzofurazan. The product showed an absorption maximum at 476 nm and a fluorescence emission peak at 533 nm in Et acetate. The optimum conditions of the reaction were investigated, and it was found that the reaction proceeded quant. at pH 8.5, 70°C in 5 min. The calibration graph is rectilinear over the range of 0.02-0.40 µg/mL. The relative standard deviation values for intraday and interday precision were 0.40-0.93 and 0.54-1.37%, resp. The proposed method was applied to the assay of REB in tablets. Mean recovery of REB from the tablets ranged between 99.91-100.20%. The results were compared statistically with those obtained by a method reported in the literature. The method is sensitive, simple, and selective, and can be used for routine quality control anal.


IT 98769-84-7, Edronax
RL: ANT (Analyte); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(spectrofluorometric determination of reboxetine in tablets)

RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-[2-ethoxyphenoxy]phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2


L16 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ACCESSION NUMBER: 2006:739581 CAPLUS
 DOCUMENT NUMBER: 146:197680
 TITLE: Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant
 AUTHOR(S): Hackett, L. Peter; Ilett, Kenneth F.; Rampono, Jonathan; Kristensen, Judith H.; Kohan, Rolland
 CORPORATE SOURCE: Clinical Pharmacology & Toxicology Laboratory, PathWest Laboratory Medicine, Nedlands, Australia
 SOURCE: European Journal of Clinical Pharmacology (2006), 62(8), 633-638
 CODEN: EJCPAS; ISSN: 0031-6970
 PUBLISHER: Springer
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The aim of this study was to investigate the transfer of reboxetine into milk, the absolute and relative infant doses via milk and to assess plasma concns. and adverse unwanted effects in the breastfed infant. Multiple samples of blood and milk were obtained over a dose interval at steady-state from four women who were taking reboxetine for postnatal depression. Drug concns. in plasma and milk were measured by high performance liquid chromatog. and milk/plasma ratio (M/P), absolute infant dose and relative infant dose were estimated by standard methods. Their four, breastfed, infants were also examined clin., and a blood sample was taken for drug anal. The median (range) dose taken by the women was 6 (4-10) mg/day. There was no significant difference in reboxetine concentration between paired fore-and hind-milk samples. The mean (95% CI) M/P was 0.06 (0.03, 0.09). Absolute infant dose was 1.7 (0.7, 2.4) µg/kg/day for reboxetine while the relative infant dose was 2.0% (1.3, 2.7%). Three of the infants met normal developmental milestones and no adverse effects were seen in any infant. The fourth infant had developmental problems that were not associated with the maternal reboxetine therapy. The concns. of reboxetine in plasma from the four infants were <4 µg/L, 2.6 µg/L, 2.3 µg/L and 5 µg/L, resp. The study suggests that reboxetine use by lactating women is safe for the breastfed infant. Nevertheless, our study had only four mother/baby pairs, and each decision to breastfeed should always be made on the basis of an individual risk/benefit anal.
 IT 98769-84-7, Edronax
 RL: ADV (Adverse effect, including toxicity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (reboxetine transfer into breastmilk, its plasma concns. and lack of adverse effects in breastfed infant)
 RN 98769-84-7 CAPLUS
 CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)
 CM 1
 CRN 71620-89-8
 CMF C19 H23 N O3
 Relative stereochemistry.

ACCESSION NUMBER: 2006:368900 CAPLUS
 DOCUMENT NUMBER: 145:328137
 TITLE: Efficacy and Tolerability of Reboxetine Compared with Citalopram: A Double-blind Study in Patients with Major Depressive Disorder
 AUTHOR(S): Langworth, Sven; Bodlund, Owe; Aagren, Hans
 CORPORATE SOURCE: Stockholm, Karolinska Institutet, and Pfizer Inc., Taebj, Swed.
 SOURCE: Journal of Clinical Psychopharmacology (2006), 26(2), 121-127
 CODEN: JCPYDR; ISSN: 0271-0749
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The objective of this study was to compare efficacy and tolerability of the selective noradrenalin reuptake inhibitor reboxetine with the selective serotonin reuptake inhibitor citalopram, in the treatment of major depressive disorder (MDD). In total, 357 outpatients with MDD were randomized to treatment with reboxetine 8-10 mg or citalopram 20-40 mg per day during 24 wk. Primary end-point was change from baseline in the Hamilton Depression Rating Scale (HAM-D, 21 items). Sexual function/dysfunction was measured by the Sexual Function scale (SF). Observed case anal. showed that both treatments yielded a gradual reduction of HAM-D scores: reboxetine with -21.4 and citalopram with -22.1 points (NS). LOCF anal. showed a greater reduction of the HAM-D scores with citalopram compared with reboxetine (-19.6 vs. -17.8; P = 0.034). The response rate was 90.3% for reboxetine and 92.7% for citalopram (NS). The most common side effect in the reboxetine group was dry mouth, and in the citalopram group sexual dysfunction. At week 24, anorgasmia was reported by 5.9% of the sexually active women in the reboxetine group vs 39% in the citalopram group. The dropout number was 91 in the reboxetine group, and 54 in the citalopram group. To summarize, both treatments gave a satisfactory antidepressant effect. The side effect profile differed between the groups, with a notably high prevalence of sexual dysfunctions in the citalopram group. The high number of dropouts in the reboxetine group, is considered as a result of the non-titration starting dose of 8 mg reboxetine per day, which gave a high incidence of early side-effects. Depressive disorders including major depression (MDD) is very common, with a lifetime prevalence of at least 15% in men and 25% in women. Depression can be treated effectively by a range of antidepressant agents. Recent reviews have suggested that the selective serotonin reuptake inhibitors (SSRIs) offer equal efficacy to the older antidepressant agents, such as tricyclic antidepressants, with the advantage of greater tolerability. Other reviewers have reported that non-SSRI antidepressants, such as clomipramine, have been found to be significantly more effective than fluoxetine for the treatment of patients with severe depression. Reboxetine (reboxetine mesylate, Edronax; Pfizer, New York) is a highly selective noradrenalin reuptake inhibitor, and the efficacy of reboxetine has been independently demonstrated in multiple randomized, double-blind, placebo-controlled studies. In addition to improvements in depressive symptoms, treatment-associated improvements in social behavior (measured




CM 2
 CRN 75-75-2
 CMF C H4 O3 S



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

using the Social Adaptation Self-evaluation Scale (SASS)), were noticed in one of these studies. In this study, reboxetine was statistically and clin. superior to both placebo and fluoxetine in improving social functioning. The primary objective of the current study was to assess efficacy and tolerability of reboxetine in comparison with those of citalopram (Cipramil; H. Lundbeck, Copenhagen, Denmark) in patients with MDD. Citalopram is a highly SSRI. The antidepressant mechanism is presumed to be a result of stimulation of serotonergic neurotransmission in the central nervous system as a consequence of higher serotonin levels resulting from inhibition of the serotonin transporter. The therapeutic efficacy of citalopram in patients with MDD has been investigated in several placebo-controlled studies and in long-term and extension studies. The underlying rationale for this comparison was to study 2 different drug profiles, 1 drug being pure 'adrenergic' and the other pure 'serotonergic'. A secondary objective was to analyze the correlation between the types of depression (ie, degree of melancholia and the efficacy of the 2 drugs).
 IT 98769-84-7, Edronax
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (reboxetine and citalopram showed similar, clin. high satisfactory efficacy in response and remission rate in treatment of major depressive disorder patient)
 RN 98769-84-7 CAPLUS
 CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)
 CM 1
 CRN 71620-89-8
 CMF C19 H23 N O3
 Relative stereochemistry.



CM 2
 CRN 75-75-2
 CMF C H4 O3 S



L16 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR
THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L16 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:301807 CAPLUS
DOCUMENT NUMBER: 144:343618
TITLE: Methods for regulating neurotransmitter systems by inducing counteradaptations
INVENTOR(S): Michalow, Alexander
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006034343	A2	20060330	WO 2005-US33826	20050923
WO 2006034343	A3	20061005		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HT, ID, IL, IN, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006069086	A1	20060330	US 2005-234850	20050923
PRIORITY APPLN. INFO.:			US 2004-612155P	P 20040923

AB The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than 1/2. The methods of the present invention may be used to address a whole host of undesirable mental and neurol. conditions.

IT 98769-84-7, Edronax

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(regulating neurotransmitter systems by inducing counteradaptations by repeatedly administering neurotransmitter receptor ligands to treat mental and neurol. disorders and combination with other agents)

RN 98769-84-7 CAPLUS

CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 71620-89-8

CMF C19 H23 N O3

Relative stereochemistry.

L16 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





CM 2
CRN 75-75-2
CMF C H4 O3 S



L16 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1200904 CAPLUS
DOCUMENT NUMBER: 143:460166
TITLE: Preparation of morpholine derivatives for regulation of monoamine transporter function
INVENTOR(S): Fish, Paul Vincent; Mackenny, Malcolm Christian; Stobie, Alan; Wakenhut, Florian; Whitlock, Gavin
Alistair
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 88 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005250775	A1	20051110	US 2005-117896	20050428
PRIORITY APPLN. INFO.:			GB 2004-9744	A 20040430
			US 2004-576337P	P 20040602

OTHER SOURCE(S): MARPAT 143:460166
GI



AB Title compds. I [R1 = H or alkyl; R2 = (un)substituted aryl, heterocycle, arylalkyl or R4; R3 each independently = alkyl, alkoxy, OH, halo, etc.;
R4 = Ph group fused to a 5-6 membered carbocyclic group or heterocyclic group]

L16 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
contg. at least one N, O or S atom; n = 0-4), and pharmaceutically acceptable salts thereof, are prep'd. and disclosed as agents to regulate monoamine transporter function. Thus, e.g., it was prep'd. by coupling of tert-Bu 2-(hydroxy(phenyl)methyl)morpholine-4-carboxylate (prepn. given) with 2-methoxy-4-chlorophenol followed by deprotection. In

norepinephrine reuptake and serotonin reuptake inhibition assays, select I possessed Ki values less than 200 nM. I should prove useful as agents in the treatment of conditions including urinary disorders, pain, premature ejaculation, ADHD and fibromyalgia. Also provided are pharmaceutical compns. comprising one or more compds. of Formula 1.

IT 869208-84-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of morpholine derivs. for regulation of monoamine transporter function)

RN 869208-84-4 CAPLUS
CN Morpholine, 2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]-, (2S)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 869183-46-0
CMF C18 H20 Cl N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S




IT 869208-86-6P 869208-87-7P 869208-91-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(X-ray powder dif action anal.; preparation of morpholine derivs. for regulation of monoamine transporter function)

L16 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).




RN 869208-91-3 CAPLUS
CN 1,2-Ethanedithiolonic acid, comp'd. with (2S)-2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 869183-46-0
CMF C18 H20 Cl N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-04-3
CMF C2 H6 O6 S2


HO3S-CH2-CH2-SO3H

L16 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 869208-86-6 CAPLUS
CN Morpholine, 2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]-, (2S)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 869183-46-0
CMF C18 H20 Cl N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 98-11-3
CMF C6 H6 O3 S




RN 869208-97-7 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, comp'd. with (2S)-2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 869183-46-0
CMF C18 H20 Cl N O3

Absolute stereochemistry. Rotation (+).




CM 2


L16 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1200903 CAPLUS
DOCUMENT NUMBER: 143:460165
TITLE: Preparation of morpholine derivatives for regulation of monoamine transporter function
INVENTOR(S): Fish, Paul Vincent; Mackenny, Malcolm Christian; Stobie, Alan; Wakenhut, Florian; Whitlock, Gavin Alistair
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer, Inc.
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105100	A1	20051110	WO 2005-1B1154	20050420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005237301	A1	20051110	AU 2005-237301	20050420
CA 2564990	A1	20051110	CA 2005-2564990	20050420
EP 1744754	A1	20070124	EP 2005-733458	20050420
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
NL 1028927	A1	20051103	NL 2005-1028927	20050429
NL 1028927	C2	20060427		
NO 2006004282	A	20061018	NO 2006-4282	20060921
PRIORITY APPLN. INFO.:			GB 2004-9744	A 20040430
			WO 2005-1B1154	W 20050420

OTHER SOURCE(S): MARPAT 143:460165
GI



I



II

AB Title compds. I (R1 = H or alkyl; R2 = (un)substituted aryl, heterocycle, arylalkyl or R4; R3 each independently = alkyl, alkoxy, OH, halo, etc.);

R4 = Ph group fused to a 5-6 membered carbocyclic group or heterocyclic group containing at least one N, O or S atom; n = 0-4, and pharmaceutically acceptable salts thereof, are prepared and disclosed as agents to regulate monoamine transporter function. Thus, e.g., II was prepared by coupling of tert-Bu 2-(hydroxy(phenyl)methyl)morpholine-4-carboxylate (preparation given) with 2-methoxy-4-chlorophenol followed by deprotection. In norepinephrine reuptake and serotonin reuptake inhibition assays, select I possessed Ki values less than 200 nM. I should prove useful as agents in the treatment of conditions including urinary disorders, pain, premature ejaculation, ADHD and fibromyalgia. Also provided are pharmaceutical compns. comprising one or more compds. of Formula I.

IT 869208-84-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of morpholine derivs. for regulation of monoamine transporter function)

RN 869208-84-4 CAPLUS

CN Morpholine, 2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]-, (2S)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 98-11-3
CMF C6 H6 O3 S




RN 869208-87-7 CAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2S)-2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 869183-46-0
CMF C18 H20 Cl N O3


Absolute stereochemistry. Rotation (+).



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 869208-91-3 CAPLUS


CN 1,2-Ethanedithiolonic acid, compd. with (2S)-2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 869183-46-0

CRN 869183-46-0
CMF C18 H20 Cl N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT 869208-86-6P 869208-87-7P 869208-91-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(x-ray powder diffraction anal.; preparation of morpholine derivs. for regulation of monoamine transporter function)


RN 869208-86-6 CAPLUS

CN Morpholine, 2-[(S)-(4-chloro-2-methoxyphenoxy)phenylmethyl]-, (2S)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 869183-46-0
CMF C18 H20 Cl N O3


Absolute stereochemistry. Rotation (+).



CM 2

CMF C18 H20 Cl N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-04-3
CMF C2 H6 O6 S2

HO3S-CH2-CH2-SO3H

REFERENCE COUNT: 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2005:1176480 CAPLUS
DOCUMENT NUMBER: 143:440426

TITLE: Substituted morpholine compounds for the treatment of central nervous system disorders, their preparation and pharmaceutical compositions

INVENTOR(S): Barta, Nancy S.; Glase, Shelly Ann; Gray, David L.; Reichard, Gregory A.; Simons, Lloyd J.; Xu, Weijian

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 85 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005245519	A1	20051103	US 2005-119210	20050429
AU 2005238296	A1	20051110	AU 2005-238296	20050419
CA 2564994	A1	20051110	CA 2005-2564994	20050419
WO 2005105763	A1	20051110	WO 2005-1B1158	20050419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1745029	A1	20070124	EP 2005-733459	20050419
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
NL 1028924	A1	20051101	NL 2005-1028924	20050429
NL 1028924	C2	20060427		
PRIORITY APPLN. INFO.:				
			US 2004-567244P	P 20040430
			WO 2005-1B1158	W 20050419


OTHER SOURCE(S): MARPAT 143:440426
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. of the formula I, which can be used in the treatment of central nervous system disorders. In compds. I, A is O or S; X is C1-10 alkyl, C2-8 alkenyl, aryl, heterocyclyl, C1-6 alkoxy, etc., with each group optionally substituted; and R1 - R5 are independently selected from H, OH, halo, C1-6 alkyl, aryl, C3-8 cycloalkyl, C2-6 alkenyl, C1-6 alkoxy, aryloxy, heterocyclyl, etc.; including pharmaceutically acceptable salts, enantiomers and diastereomers. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically

RN 868687-84-7 CAPLUS
CN Morpholine, 2-[(S)-[4-fluoro-2-(methylthio)phenoxy]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 868687-85-8 CAPLUS
CN Morpholine, 2-[(S)-[4-fluoro-2-(methylthio)phenoxy]phenylmethyl]-, (2S)-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 868687-84-7
CMP C18 H20 F N O2 S


Absolute stereochemistry.



CM 2

CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.



acceptable carrier, as well as to the use of the compns. in the treatment of central nervous system disorders. Ring opening of (R,R)-phenylglycidol with 1-naphthol followed by silylation of the primary alc., mesylation of the secondary alc., and desilylation gave mesylate II, which underwent ring closure to the epoxide, ring opening with ammonium hydroxide and amidation with chloroacetyl chloride, resulting in the formation of amide III. Compd. III was converted to the morpholine by intramol. cyclization and Red-Al redn. to give morpholine IV. Several compds., e.g., IV, express high inhibition of human norepinephrine transporter (hNET) and human serotonin transporter (hSERT).

IT 868685-38-5P 868686-05-9P 868686-06-0P
868687-84-7P 868687-85-8P 868687-91-6P,
2-[(2-Ethylsulfonylphenoxy)phenylmethyl]morpholine 868688-35-1P
868688-36-2P 868689-57-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of substituted morpholine compds. for

treatment of CNS disorders)

RN 868685-38-5 CAPLUS

CN Morpholine, 2-[(S)-[2-(ethylthio)phenoxy]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868686-05-9 CAPLUS

CN Morpholine, 2-[(S)-[2-(methylthio)phenoxy]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868686-06-0 CAPLUS


CN Morpholine, 2-[(S)-[2-(methylsulfonyl)phenoxy]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 868687-91-6 CAPLUS
CN Morpholine, 2-[(S)-[2-(ethylthio)phenoxy]phenylmethyl]- (9CI) (CA INDEX NAME)


RN 868688-35-1 CAPLUS

CN Morpholine, 2-[(S)-[2-(methylthio)phenoxy]phenylmethyl]- (9CI) (CA INDEX NAME)




RN 868688-36-2 CAPLUS

CN Morpholine, 2-[(S)-[2-(methylsulfonyl)phenoxy]phenylmethyl]- (9CI) (CA INDEX NAME)



RN 868689-57-0 CAPLUS

CN Morpholine, 2-[(S)-[4-fluoro-2-(methylthio)phenoxy]phenylmethyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2005:1105437 CAPLUS

DOCUMENT NUMBER: 143:452076

TITLE: Equilibrium sampling through membrane based on a single hollow fibre for determination of drug-protein binding and free drug concentration in plasma
 AUTHOR(S): Trtic-Petrovic, Tatjana; Liu, Jing-Fu; Joensson, Jan Aake
 CORPORATE SOURCE: Vinca Institute of Nuclear Sciences, Laboratory of Physics, Belgrade, 11001,
 SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2005), 826(1-2), 169-176
 CODEN: JCBAAI; ISSN: 1570-0232

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The determination of drug-protein binding and free drug concentration in plasma applying the equilibrium sampling through membrane (ESTM) technique has been studied using supported liquid membrane extraction in a single hollow fiber without any membrane carrier. In the extraction setup, the donor phase (plasma or buffer) was placed in the vial, into which was immersed the hollow fiber with the acceptor phase situated in the lumen. This proposed technique was applied to study the drug-protein binding of five local anesthetics and two antidepressants as model substances, and the influence of the total drug concentration on the drug-protein binding was investigated. The brief theor. background for determination of the drug-protein binding under equilibrium conditions is described. The developed method shows a new, improved and simple procedure for determination of free drug concentration in plasma and extent of drug-protein binding.

IT 98769-84-7
 RL: PKT (Pharmacokinetics); BIOL (Biological study)
 (equilibrium sampling through membrane based on a single hollow fiber

for determination of drug-protein binding and free drug concentration in plasma)

RN 98769-84-7 CAPLUS

CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 71620-89-8

CMF C19 H23 N O3

Relative stereochemistry.

L16 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L16 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2005:614812 CAPLUS

DOCUMENT NUMBER: 143:266876

TITLE: Enantioselective synthesis of (2R,3R)- and (2S,3S)-2-[(3-chlorophenyl)-(2-methoxyphenoxy)methyl]morpholine
 AUTHOR(S): Harding, Wayne W.; Hodge, Matthias; Wang, Zhixia; Woolverton, William L.; Parrish, Damon; Deschamps, Jeffrey R.; Prisinzano, Thomas E.
 CORPORATE SOURCE: College of Pharmacy, Division of Medicinal & Natural Products Chemistry, The University of Iowa, Iowa City,
 IA, 52242, USA

SOURCE: Tetrahedron: Asymmetry (2005), 16(13), 2249-2256

CODEN: TASYE3; ISSN: 0957-4166


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:266876

GI



AB The enantioselective syntheses of the (R,R)- and (S,S)-enantiomers of I from com. available 3-chlorocinnamic acid is reported. The Sharpless asym. epoxidn. was used to establish the stereocenters in the synthesis

of both enantiomers of I.

IT 863969-87-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of

(chlorophenyl(methoxyphenoxy)methyl)arylsulfonylmorpholine and norepinephrine uptake inhibitory activity starting from chlorocinnamate using a multistep procedure)

RN 863969-87-3 CAPLUS

CN Morpholine, 2-[(3-chlorophenyl)-(2-methoxyphenoxy)methyl]-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L16 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

2005:588645 CAPLUS
143:115550

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060949	A2	20050707	WO 2004-US38221	20041201
WO 2005060949	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2548304	A1	20050707	CA 2004-2548304	20041201
EP 1729754	A2	20061213	EP 2004-811076	20041201
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1889940	A	20070103	CN 2004-80036841	20041201
US 2007015786	A1	20070118	US 2006-581015	20060530
PRIORITY APPL. INFO.:			US 2003-529428P	P 20031212
			WO 2004-US38221	W 20041201

OTHER SOURCE(S):


GI

MARPAT 143:115550




AB The invention relates to a method of preventing or treating hot flashes,

(Continued)



RN 668470-58-4 CAPLUS
CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-59-5 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-60-8 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

(Continued)

vasomotor symptoms, impulse control disorders or personality change due to

a general medical condition, comprising administering to a patient in need thereof a therapeutically effective amt. of a selective norepinephrine reuptake inhibitor selected from atomoxetine, reboxetine, I [X = alkylthio; Y = alkyl], II [n = 1-3; R1 = alkyl, alkenyl, cycloalkyl, etc.],

R2-R4 = H, alkyl, alkoxy, etc.; R5-R6 = H, alkyl, alkoxy, halo; R7-R8 = H,

alkyl; R9-R10 = H, halo, OH, CN, alkyl, alkoxy, etc. Over 200 title compds. such as I, II and other heterocyclic compds. disclosed, were prepd. E.g., a 2-step synthesis of N-(2-methylpropyl)-N-[(2-fluorophenyl)methyl]piperidin-4-amine fumarate, starting from tert-Bu 4-(2-methylpropylamino)piperidine-1-carboxylate and 2-fluorobenzaldehyde, was given. The preferred exemplified title compds. exhibit a Ki value less than 1 μ M, more preferably less than 500 nM at the norepinephrine transporter as detd. using the scintillation proximity assay.

IT 668470-56-2P 668470-57-3P 668470-58-4P
668470-59-5P 668470-60-8P 668470-61-9P
668470-62-0P 668470-63-1P 668470-64-2P
668470-65-3P 668470-66-4P 668470-67-5P
668470-68-6P 668470-69-7P 668470-70-0P
668470-71-1P 668470-72-2P 668470-73-3P
668470-74-4P 668470-76-6P 668470-77-7P
668470-78-8P 668470-79-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of heterocyclic compds. as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to general medical condition)

RN 668470-56-2 CAPLUS

CN Morpholine, 2-[(S)-phenyl[2-(trifluoromethyl)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-57-3 CAPLUS
CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(Continued)



● HCl


RN 668470-61-9 CAPLUS
CN Morpholine, 2-[(S)-[1,1'-biphenyl]-2-ylthio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-62-0 CAPLUS
CN Morpholine, 2-[(S)-[1,1'-biphenyl]-2-ylthio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-63-1 CAPLUS
CN Morpholine, 2-[(S)-[2-(fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-64-2 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-ethylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-65-3 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methoxyphenyl)thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



● HCl


RN 668470-66-4 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-71-1 CAPLUS
CN Morpholine, 2-[(S)-phenyl[2-(2-propylphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-72-2 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-73-3 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 668470-67-5 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-68-6 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-69-7 CAPLUS
CN Morpholine, 2-[(S)-phenyl[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-70-0 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-74-4 CAPLUS
CN Morpholine, 2-[(S)-(3-fluorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-76-6 CAPLUS
CN Morpholine, 2-[(S)-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-77-7 CAPLUS
CN Morpholine, 2-[(S)-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-78-8 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-79-9 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, hydrochloride, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


IT 667876-61-1P 667876-73-5P 667876-84-8P

Relative stereochemistry.



RN 668470-75-5 CAPLUS
CN Morpholine, 2-[(S)-(3-fluorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, hydrochloride, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-88-0 CAPLUS
CN Morpholine, 4-[(1R)-1-phenylethyl]-2-[(R)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-89-1 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(S)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

667876-86-0P 668470-75-5P 668470-88-0P
668470-89-1P 668470-90-4P 668470-91-5P
668470-92-6P 668470-95-9P 668470-97-1P
668471-00-9P 668471-02-1P 668471-04-3P
847687-22-3P 847687-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclic compds. as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to general medical condition)


RN 667876-61-1 CAPLUS
CN Morpholine, 2-[(R)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-73-5 CAPLUS
CN Morpholine, 2-[(R)-[(2-methylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-84-8 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-86-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)




RN 668470-90-4 CAPLUS
CN Morpholine, 2-[(S)-[(2-(methylthio)phenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-91-5 CAPLUS
CN Morpholine, 2-[(S)-[(2-(1-methylethyl)phenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-92-6 CAPLUS
CN Morpholine, 2-[(S)-[(1,1'-biphenyl)-2-ylthio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-95-9 CAPLUS
CN Morpholine, 2-[(R)-[(2-(1-methylethoxy)phenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-97-1 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenylthio]methyl-2-(trifluoromethoxy)phenylthio]methyl-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 668471-00-9 CAPLUS
CN Benzoic acid, 2-[[[(R)-phenylthio]methyl]-4-(phenylmethyl)-2-morpholinyl]methylthio]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-02-1 CAPLUS
CN Morpholine, 2-[(R)-3-(fluorophenyl)[(2-(trifluoromethyl)phenylthio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-04-3 CAPLUS
CN Morpholine, 2-[(R)-4-(chlorophenyl)[(2-(trifluoromethyl)phenylthio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 847687-22-3 CAPLUS
CN Morpholine, 2-[(R)-[(2-(fluorophenyl)thio)phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 847687-24-5 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenylthio]methyl-2-(2-propylphenylthio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

ACCESSION NUMBER: 2005:531541 CAPLUS
DOCUMENT NUMBER: 143:90865
TITLE: Chronic reboxetine desensitizes terminal but not somatodendritic α_2 -adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus
AUTHOR(S): Parini, Stefania; Renoldi, Giuliano; Battaglia, Angelo; Invernizzi, Roberto W.
CORPORATE SOURCE: Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
SOURCE: Neuropsychopharmacology (2005), 30(6), 1048-1055
CODEN: NEROEW; ISSN: 0893-133X
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 'The slow onset of antidepressant drugs' effects is thought to reflect the time required for the development of adaptive changes such as desensitization of presynaptic autoreceptors controlling the release of neurotransmitters. Using in vivo microdialysis in conscious rats, we studied the effect of a continuous infusion of the selective noradrenaline (NA) reuptake inhibitor reboxetine on extracellular concns. of NA. Doses of 10 mg/kg/day reboxetine through s.c. osmotic pumps for 2 days increased extracellular NA by 272% in the dorsal hippocampus (DH) of rats. NA rose significantly more in rats given reboxetine for 7 (469%) and 14 (437%) days. I.p. injection of 30 μ g/kg clonidine, an α_2 -adrenoceptor agonist, reduced the release of NA to 49% of basal levels in rats given vehicle or reboxetine for 2 days, but this effect was markedly less in rats given reboxetine for 7 and 14 days. Likewise, the effect of intrahippocampal infusion of clonidine (0.05 and 0.2 μ M) on extracellular NA was significantly attenuated in rats given reboxetine for 7 and 14 days, whereas the injection of 0.6 nmol clonidine into the locus coeruleus caused similar redns. of extracellular NA in the DH and prefrontal cortex (PFC) of rats infused with vehicle (DH -64%; PFC -42%) and reboxetine (DH -45%; PFC -28%) for 14 days. The results indicate that chronic treatment markedly enhances the effect of reboxetine on extracellular NA in the DH and suggest that this effect may be due to the desensitization of hippocampal α_2 -adrenoceptors.
IT 98769-84-7, Reboxetine mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chronic reboxetine methanesulfonate desensitizes terminal but not somatodendritic α_2 -adrenoceptor enhancing extracellular noradrenaline release in rat dorsal hippocampus)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-2-(ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CHF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S


REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L16 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:529091 CAPLUS
DOCUMENT NUMBER: 143:393190
TITLE: Determination of Residual Organic Solvents in Reboxetine Mesylate by Capillary GC
AUTHOR(S): LU, Dan
CORPORATE SOURCE: Shanghai Institute for Drug Control, Shanghai, 200233, Peop. Rep. China
SOURCE: Zhongguo Yiyao Gongye Zazhi (2004), 35(8), 492-493
CODEN: ZYGZEA; ISSN: 1001-8255
PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB A simple capillary GC method for the determination of residual organic solvents, ethanol, dichloromethane, t-butanol, iso-Pr ether, Et acetate, 1,4-dioxane, pyridine and toluene, in reboxetine mesylate was established.
A DB-624 capillary column was used with procedural column temperature control.
The calibration curves were linear ($r > 0.99$). The average recoveries were 86.6%-106.6%. The detection limits were 0.092-1.6 µg/mL.
IT 98769-84-7, Reboxetine Mesylate
RL: AMX (Analytical matrix); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(determination of residual organic solvents in reboxetine mesylate by capillary GC)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.




CM 2

CRN 75-75-2
CMF C H4 O3 S

L16 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:523264 CAPLUS
DOCUMENT NUMBER: 143:59831
TITLE: A preparation of aminopiperidine derivatives, useful for the treatment of cognitive failure
INVENTOR(S): Hatfield, Alan Kramer; Bynaster, Franklin Porter; McKinzie, David Lee; Tucker, Tina Marie; Keaffaber, Kirk Matthew; Summer, Calvin Russell; Trzepacz, Paula Terese; Allen, Albert John; Kelsey, Douglas Kenneth; Michelson, David; Gehlert, Donald Richard; Yang, Charles Renkin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053663	A2	20050616	WO 2004-US37195	20041124
WO 2005053663	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-524450P	P 20031124
			US 2003-524781P	P 20031125

OTHER SOURCE(S): MARPAT 143:59831
GI




AB The invention relates to a preparation of aminopiperidine derivs. of formula I
[wherein: x is 1-3; R1 is (un)substituted phenyl; R2 and R5 are independently H or alkyl; R3 is (cyclo)alkyl, alkenyl, or cycloalkylalkyl, etc.; R4 is H, halogen, or OH, etc.; R6 is H, halogen, CN, or alkyl,

L16 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 etc.), useful for the treatment of cognitive failure. Selective
 norepinephrine reuptake inhibitors were used to treat cognitive failure.
 For instance, fumarate salt of aminopiperidine deriv. II was prep'd. via
 imination of 2-fluorobenzaldehyde by tert-Bu 4-[(2-
 methylpropyl)amino]piperidine-1-carboxylate, redn. of the obtained imine,
 and subsequent fumaric acid salt formation. The preferred invention
 compds. exhibit Ki values less than 500 nM at the norepinephrine
 transporter.


IT 668470-56-2P 668470-57-3P 668470-58-4P
 668470-59-5P 668470-60-8P 668470-61-9P
 668470-62-0P 668470-63-1P 668470-64-2P
 668470-65-3P 668470-66-4P 668470-67-5P
 668470-68-6P 668470-69-7P 668470-70-0P
 668470-71-1P 668470-72-2P 668470-73-3P
 668470-74-4P 668470-75-5P 668470-76-6P
 668470-77-7P 668470-78-8P 668470-79-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of aminopiperidine derivs. useful for the treatment of
 cognitive failure)
 RN 668470-56-2 CAPLUS
 CN Morpholine, 2-[(S)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-57-3 CAPLUS
 CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-58-4 CAPLUS
 CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L16 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668470-62-0 CAPLUS
 CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-63-1 CAPLUS
 CN Morpholine, 2-[(S)-[2-(2-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 668470-64-2 CAPLUS
 CN Morpholine, 2-[(S)-[2-(2-ethylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl


RN 668470-59-5 CAPLUS
 CN Morpholine, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-60-8 CAPLUS
 CN Morpholine, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 668470-61-9 CAPLUS
 CN Morpholine, 2-[(S)-[2-(1,1'-biphenyl)-2-ylthio]phenylmethyl]-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 668470-65-3 CAPLUS
 CN Morpholine, 2-[(S)-[2-(2-ethylphenyl)thio]phenylmethyl]-, hydrochloride,
 (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-66-4 CAPLUS
 CN Morpholine, 2-[(S)-[2-(2-methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-67-5 CAPLUS
 CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-68-6 CAPLUS
 CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-69-7 CAPLUS
CN Morpholine, 2-[(S)-phenyl[[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-70-0 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-71-1 CAPLUS
CN Morpholine, 2-[(S)-phenyl[[2-(propylphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-75-5 CAPLUS
CN Morpholine, 2-[(S)-[3-(3-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 668470-76-6 CAPLUS
CN Morpholine, 2-[(S)-[4-chlorophenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-77-7 CAPLUS
CN Morpholine, 2-[(S)-[4-chlorophenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)




RN 668470-72-2 CAPLUS
CN Benzoic acid, 2-[(S)-[2-(2-morpholinyl)phenyl]thio]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-73-3 CAPLUS
CN Benzoic acid, 2-[(S)-[2-(2-morpholinyl)phenyl]thio]methyl]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 668470-74-4 CAPLUS
CN Morpholine, 2-[(S)-[3-(3-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



● HCl


RN 668470-78-8 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-79-9 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methoxyphenyl)thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 667876-61-1P 667876-73-5P 667876-84-8P
 667876-86-0P 668470-88-0P 668470-89-1P
 668470-90-4P 668470-91-5P 668470-92-6P
 668470-95-9P 668470-97-1P 668471-00-9P
 668471-02-1P 668471-04-3P 847687-22-3P
 847687-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminopiperidine derivs. useful for the treatment of cognitive failure)



RN 667876-61-1 CAPLUS
 CN Morpholine, 2-[(R)-(2-fluorophenyl){[(2-methoxyphenyl)thio]methyl}-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-73-5 CAPLUS
 CN Morpholine, 2-[(R)-{[(2-methylphenyl)thio]phenylmethyl}-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-90-4 CAPLUS
 CN Morpholine, 2-[(S)-{[(2-(methylthio)phenyl)thio]phenylmethyl}-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-91-5 CAPLUS
 CN Morpholine, 2-[(S)-{[(2-(1-methylethyl)phenyl)thio]phenylmethyl}-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-92-6 CAPLUS
 CN Morpholine, 2-[(S)-{[(1,1'-biphenyl)-2-ylthio]phenylmethyl}-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-95-9 CAPLUS
 CN Morpholine, 2-[(R)-{[(2-(1-methylethoxy)phenyl)thio]phenylmethyl}-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 667876-84-8 CAPLUS
 CN Morpholine, 2-[(R)-{[(2-ethylphenyl)thio]phenylmethyl}-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-86-0 CAPLUS
 CN Morpholine, 2-[(R)-{[(2-methoxyphenyl)thio]phenylmethyl}-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-88-0 CAPLUS
 CN Morpholine, 4-[(1R)-1-phenylethyl]-2-[(R)-phenyl{[2-(trifluoromethyl)phenyl]thio]methyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-89-1 CAPLUS
 CN Morpholine, 4-(phenylmethyl)-2-[(S)-phenyl{[2-(trifluoromethoxy)phenyl]thio]methyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-97-1 CAPLUS
 CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenyl{[2-(trifluoromethoxy)phenyl]thio]methyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-00-9 CAPLUS
 CN Benzoic acid, 2-[(R)-phenyl{[2-(4-(phenylmethyl)-2-morpholinyl)methyl]thio}-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-02-1 CAPLUS
 CN Morpholine, 2-[(R)-{[(3-fluorophenyl){[2-(trifluoromethyl)phenyl]thio]methyl}-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-04-3 CAPLUS
 CN Morpholine,
 2-[(R)-(4-chlorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-
 4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 847687-22-3 CAPLUS
 CN Morpholine, 2-[(R)-(2-fluorophenyl)thio]phenylmethyl]-4-(phenylmethyl)-,
 (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 847687-24-5 CAPLUS
 CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenyl[(2-propylphenyl)thio]methyl]-,
 (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

ACCESSION NUMBER: 2005:216719 CAPLUS
 DOCUMENT NUMBER: 142:291416
 TITLE: Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
 INVENTOR(S): Kelsey, Douglas Kenneth
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 299 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021095	A2	20050310	WO 2004-US25591	20040825
WO 2005021095	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2532349	A1	20050310	CA 2004-2532349	20040825
EP 1660185	A2	20060531	EP 2004-780429	20040825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2007032554	A1	20070208	US 2006-568269	20060214
PRIORITY APPLN. INFO.: US 2003-498018P P 20030827				
WO 2004-US25591 W 20040825				

OTHER SOURCE(S): MARPAT 142:291416
 GI



AB Provided are methods and medicaments for treating stuttering or another communication disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent Number 5,281,624],


as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the preparation of addnl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine derivative II-HCl was prepared via alkylation of (4-benzyl-morpholin-2-yl)(phenyl)methanone with 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation. The preferred invention compds. exhibited Ki values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).

IT 668470-56-2P 668470-57-3P 668470-58-4P
 668470-59-5P 668470-60-8P 668470-61-9P
 668470-62-0P 668470-63-1P 668470-64-2P
 668470-65-3P 668470-66-4P 668470-67-5P
 668470-68-6P 668470-69-7P 668470-70-0P
 668470-71-1P 668470-72-2P 668470-73-3P
 668470-74-4P 668470-75-5P 668470-76-6P
 668470-77-7P 668470-78-8P 668470-79-9P
 847687-23-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)

RN 668470-56-2 CAPLUS


L16 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Morpholine, 2-[(S)-phenyl[[2-(trifluoromethyl)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-57-3 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(methylthio)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-58-4 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(methylthio)phenyl]thio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 668470-59-5 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethyl)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L16 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl


RN 668470-63-1 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(2-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 668470-64-2 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(2-ethylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 668470-65-3 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(2-ethylphenyl)thio]phenylmethyl]-, hydrochloride,
 (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L16 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668470-60-8 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethyl)phenyl]thio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-61-9 CAPLUS
 CN Morpholine, 2-[(S)-[[1,1'-biphenyl]-2-ylthio]phenylmethyl]-, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-62-0 CAPLUS
 CN Morpholine, 2-[(S)-[[1,1'-biphenyl]-2-ylthio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L16 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl


RN 668470-66-4 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(2-methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-67-5 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-68-6 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-,
 hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-69-7 CAPLUS
CN Morpholine, 2-[(S)-phenyl[[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-70-0 CAPLUS
CN Morpholine, 2-[(S)-[(2-methylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-71-1 CAPLUS
CN Morpholine, 2-[(S)-phenyl[(2-propylphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-75-5 CAPLUS
CN Morpholine, 2-[(S)-[3-fluorophenyl][(2-(trifluoromethyl)phenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 668470-76-6 CAPLUS
CN Morpholine, 2-[(S)-[4-chlorophenyl][(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-77-7 CAPLUS
CN Morpholine, 2-[(S)-[4-chlorophenyl][(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)




RN 668470-72-2 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-73-3 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-74-4 CAPLUS
CN Morpholine, 2-[(S)-[3-fluorophenyl][(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-78-8 CAPLUS
CN Morpholine, 2-[(S)-[2-fluorophenyl][(2-methoxyphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-79-9 CAPLUS
CN Morpholine, 2-[(S)-[2-fluorophenyl][(2-methoxyphenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 847687-23-4 CAPLUS
CN Morpholine, 2-[(S)-[(2-fluorophenyl)thio]phenylmethyl]-, hydrochloride, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 667876-61-1P 667876-73-5P 667876-84-8P
667876-86-0P 668470-88-0P 668470-89-1P
668470-90-4P 668470-91-5P 668470-92-6P
668470-95-9P 668470-97-1P 668471-00-5P
668471-02-1P 668471-04-3P 847687-22-3P
847687-24-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)

RN 667876-61-1 CAPLUS
CN Morpholine, 2-[(R)-[(2-fluorophenyl)thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L16 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Morpholine, 4-[(1R)-1-phenylethyl]-2-[(R)-phenyl]2-(trifluoromethyl)phenylthio]methyl]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-89-1 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(S)-phenyl]2-(trifluoromethyl)phenylthio]methyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-90-4 CAPLUS
CN Morpholine, 2-[(S)-[[2-(methylthio)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-91-5 CAPLUS
CN Morpholine, 2-[(S)-[[2-(1-methylethyl)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-92-6 CAPLUS




RN 667876-73-5 CAPLUS
CN Morpholine, 2-[(R)-[(2-methylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-84-8 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667876-86-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 668470-88-0 CAPLUS


L16 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Morpholine, 2-[(S)-[[1,1'-biphenyl]-2-ylthio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-95-9 CAPLUS
CN Morpholine, 2-[(R)-[[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-97-1 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenyl]2-(trifluoromethoxy)phenylthio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-00-9 CAPLUS
CN Benzoic acid, 2-[(R)-phenyl]2-(4-(phenylmethyl)-2-morpholinylmethylthio]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-02-1 CAPLUS
 CN Morpholine, 2-[(R)-(3-fluorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl
]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-04-3 CAPLUS
 CN Morpholine, 2-[(R)-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl
]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 847687-22-3 CAPLUS
 CN Morpholine, 2-[(R)-(2-fluorophenyl)thio]phenylmethyl]-4-(phenylmethyl)-,
 (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 847687-24-5 CAPLUS
 CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenyl[(2-propylphenyl)thio]methyl]-,

ACCESSION NUMBER: 2005:216660 CAPLUS
 DOCUMENT NUMBER: 142:291415
 TITLE: Treatment of pervasive development disorders
 employing
 norepinephrine reuptake inhibitors
 Allen, Albert John; Kelsey, Douglas Kenneth
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 300 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020976	A2	20050310	WO 2004-US25593	20040825
WO 2005020976	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2336161	A1	20050310	CA 2004-2336161	20040825
EP 1660065	A2	20060531	EP 2004-780431	20040825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006241188	A1	20061026	US 2006-568466	20060214
PRIORITY APPLN. INFO.:			US 2003-498146P	P 20030827
			WO 2004-US25593	W 20040825

OTHER SOURCE(S): MARPAT 142:291415
 GI



AB Provided are methods and medicaments for treating a pervasive development disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.
 The

Relative stereochemistry.



invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent No. 5,281,624], as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the prepn. of addnl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine deriv. II=HCl (R = H) was prepd. via alkylation of (4-benzyl-morpholin-2-yl)(phenyl)methanone by 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation of the obtained alc. I (R = Bn). The preferred

invention compds. exhibited Ki values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).


IT 668470-56-2P 668470-57-3P 668470-58-4P
 668470-59-5P 668470-60-8P 668470-61-9P
 668470-62-0P 668470-63-1P 668470-64-2P
 668470-65-3P 668470-66-4P 668470-67-5P
 668470-68-6P 668470-69-7P 668470-70-0P
 668470-71-1P 668470-72-2P 668470-73-3P
 668470-74-4P 668470-75-5P 668470-76-6P
 668470-77-7P 668470-78-8P 668470-79-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)


RN 668470-56-2 CAPLUS
 CN Morpholine, 2-[(S)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-57-3 CAPLUS
 CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl]-, (2S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-58-4 CAPLUS

L16 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Morpholine, 2-[(S)-[[2-(methylthio)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-59-5 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethyl)phenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-60-8 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethyl)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 668470-61-9 CAPLUS
 CN Morpholine, 2-[(S)-[[1,1'-biphenyl]-2-ylthio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Morpholine, 2-[(S)-[[2-(ethylphenyl)thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-66-4 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-67-5 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-68-6 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L16 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668470-62-0 CAPLUS
 CN Morpholine, 2-[(S)-[[1,1'-biphenyl]-2-ylthio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-63-1 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(2-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-64-2 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(2-ethylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-65-3 CAPLUS


L16 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl


RN 668470-69-7 CAPLUS
 CN Morpholine, 2-[(S)-phenyl[[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-70-0 CAPLUS
 CN Morpholine, 2-[(S)-[[2-(2-methylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-71-1 CAPLUS
 CN Morpholine, 2-[(S)-phenyl[[2-(propylphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-72-2 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-73-3 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 668470-74-4 CAPLUS
CN Morpholine, 2-[(S)-(3-fluorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



● HCl


RN 668470-78-8 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-79-9 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-75-5 CAPLUS
CN Morpholine, 2-[(S)-(3-fluorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 668470-76-6 CAPLUS
CN Morpholine, 2-[(S)-(4-chlorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-77-7 CAPLUS
CN Morpholine, 2-[(S)-(4-chlorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)



● HCl

RN 847687-23-4 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


IT 667876-61-1P 667876-73-5P 667876-84-8P
667876-86-0P 668470-88-0P 668470-89-1P
668470-90-4P 668470-91-5P 668470-92-6P
668470-95-9P 668470-97-1P 668471-00-9P
668471-02-1P 668471-04-3P 847687-22-3P
847687-24-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)
RN 667876-61-1 CAPLUS
CN Morpholine, 2-[(R)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-73-5 CAPLUS
CN Morphinolone, 2-[(R)-[2-(2-methylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-84-8 CAPLUS
CN Morphinolone, 2-[(R)-[2-(2-methylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667876-86-0 CAPLUS
CN Morphinolone, 2-[(R)-[2-(2-methoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 668470-88-0 CAPLUS


CN Morphinolone, 2-[(S)-[2-(1,1'-biphenyl)-2-ylthio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-95-9 CAPLUS
CN Morphinolone, 2-[(R)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-97-1 CAPLUS
CN Morphinolone, 4-(phenylmethyl)-2-[(R)-phenyl[[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-00-9 CAPLUS
CN Benzoic acid, 2-[(R)-phenyl[[2-(2-phenylmethyl)-2-morpholinyl]methyl]thio]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




CN Morphinolone, 4-[(1R)-1-phenylethyl]-2-[(R)-phenyl[[2-(trifluoromethyl)phenyl]thio]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-89-1 CAPLUS
CN Morphinolone, 4-(phenylmethyl)-2-[(S)-phenyl[[2-(trifluoromethyl)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-90-4 CAPLUS
CN Morphinolone, 2-[(S)-[2-(2-methylthio)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-91-5 CAPLUS
CN Morphinolone, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-92-6 CAPLUS


RN 668471-02-1 CAPLUS
CN Morphinolone, 2-[(R)-[2-(3-fluorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-04-3 CAPLUS
CN Morphinolone, 2-[(R)-[2-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 847687-22-3 CAPLUS
CN Morphinolone, 2-[(R)-[2-(2-fluorophenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 847687-24-5 CAPLUS
CN Morphinolone, 4-(phenylmethyl)-2-[(R)-phenyl[[2-(2-propylphenyl)thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L16 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:216659 CAPLUS
DOCUMENT NUMBER: 142:291414
TITLE: Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
INVENTOR(S): Sumner, Calvin Russell
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020975	A2	20050310	WO 2004-US25592	20040825
WO 2005020975	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2530014	A1	20050310	CA 2004-2530014	20040825
EP 1660064	A2	20060531	EP 2004-780430	20040825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:				
				WO 2004-US25592 W 20040825


OTHER SOURCE(S): MARPAT 142:291414
GI



AB or Provided are methods and medicaments for treating a learning disability as a motor skills disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent Number 5,281,624], as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the preparation of addnl. heterocyclic deriva. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine derivative II*HCl was prepared via alkylation of (4-benzyl-morpholin-2-yl)(phenyl)methanone with 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation. The preferred invention compds. exhibited Ki values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).


IT 668470-56-2P 668470-57-3P 668470-58-4P
668470-59-5P 668470-60-8P 668470-61-9P
668470-62-0P 668470-63-1P 668470-64-2P
668470-65-3P 668470-66-4P 668470-67-5P
668470-68-6P 668470-69-7P 668470-70-0P
668470-71-1P 668470-72-2P 668470-73-3P
668470-74-4P 668470-75-5P 668470-76-6P
668470-77-7P 668470-78-8P 668470-79-9P
847687-23-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)

Absolute stereochemistry.




RN 668470-57-3 CAPLUS
CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-58-4 CAPLUS
CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl-, hydrochloride, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl


RN 668470-59-5 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-60-8 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-61-9 CAPLUS
CN Morpholine, 2-[(S)-[2-(1,1'-biphenyl)-2-ylthio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-62-0 CAPLUS
CN Morpholine, 2-[(S)-[2-(1,1'-biphenyl)-2-ylthio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-63-1 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-64-2 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-ethylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-65-3 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-ethylphenyl)thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-66-4 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-67-5 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-68-6 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-69-7 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-(trifluoromethoxy)phenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-70-0 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-71-1 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-propylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-72-2 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-73-3 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 668470-74-4 CAPLUS
CN Morpholine, 2-[(S)-(3-fluorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



● HCl


RN 668470-78-8 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-79-9 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-75-5 CAPLUS
CN Morpholine, 2-[(S)-(3-fluorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 668470-76-6 CAPLUS
CN Morpholine, 2-[(S)-(4-chlorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-77-7 CAPLUS
CN Morpholine, 2-[(S)-(4-chlorophenyl)[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)



● HCl

RN 847687-23-4 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


IT 667876-61-1P 667876-73-5P 667876-84-8P
667876-86-0P 668470-88-0P 668470-89-1P
668470-90-4P 668470-91-5P 668470-92-6P
668470-95-9P 668470-97-1P 668471-00-9P
668471-02-1P 668471-04-3P 847687-22-3P
847687-24-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)
RN 667876-61-1 CAPLUS
CN Morpholine, 2-[(R)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-73-5 CAPLUS
CN Morphinolone, 2-[(R)-[2-(4-methoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-84-8 CAPLUS
CN Morphinolone, 2-[(R)-[2-(4-methylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667876-86-0 CAPLUS
CN Morphinolone, 2-[(R)-[2-(4-ethoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 668470-88-0 CAPLUS


L16 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Morphinolone, 2-[(S)-[2-(1,1'-biphenyl)-2-ylthio]phenylmethyl]-4-(phenylmethyl)-, (2S)-rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-95-9 CAPLUS
CN Morphinolone, 2-[(S)-[2-(1-methylethoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-97-1 CAPLUS
CN Morphinolone, 4-(phenylmethyl)-2-[(R)-phenyl[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-00-9 CAPLUS
CN Benzoic acid, 2-[(R)-phenyl[2-(4-(phenylmethyl)-2-morpholinyl)methyl]thio]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L16 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Morphinolone, 4-[(1R)-1-phenylethyl]-2-[(R)-phenyl[2-(trifluoromethyl)phenyl]thio]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-89-1 CAPLUS
CN Morphinolone, 4-(phenylmethyl)-2-[(S)-phenyl[2-(trifluoromethyl)phenyl]thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-90-4 CAPLUS
CN Morphinolone, 2-[(S)-[2-(4-methylthio)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-91-5 CAPLUS
CN Morphinolone, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-92-6 CAPLUS

L16 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 668471-02-1 CAPLUS
CN Morphinolone, 2-[(R)-[2-(3-fluorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-04-3 CAPLUS
CN Morphinolone, 2-[(R)-[2-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 847687-22-3 CAPLUS
CN Morphinolone, 2-[(R)-[2-(3-fluorophenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 847687-24-5 CAPLUS
CN Morphinolone, 4-(phenylmethyl)-2-[(R)-phenyl[2-(2-propylphenyl)thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L16 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:99358 CAPLUS
DOCUMENT NUMBER: 142:162694
TITLE: Medicinal compositions containing adenosine A2A receptor antagonists and other antidepressants
INVENTOR(S): Kase, Hiroshi; Kobayashi, Minoru; Shiozaki, Shizuo; Mori, Akihisa; Seno, Naoki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009444	A1	20050203	WO 2004-JP10758	20040722
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2533117	A1	20050203	CA 2004-2533117	20040722
EP 1655029	A1	20060510	EP 2004-748023	20040722
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 2006241102	A1	20061026	US 2006-565239	20060119
NO 2006000958	A	20060425	NO 2006-958	20060227
PRIORITY APPLN. INFO.:			JP 2003-201549	A 20030725
			WO 2004-JP10758	W 20040722

AB It is intended to provide medicinal compns. and the like useful in treating depression which contain a compound having an antagonism to adenosine A2A receptor (for example, (E)-8-(3,4-dimethoxytyrlyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purin-2,6-dione) (I) or a pharmacol. acceptable salt thereof together with an antidepressant (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenaline reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin/noradrenaline reuptake inhibitor, a monoamine oxidase inhibitor or a serotonin 2 antagonist). The effect of combination of I 0.08 and venlafaxine hydrochloride 5 mg/kg on depression in mice in forced swim test was examined
IT 98769-84-7, Reboxetine mesylate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicinal compns. containing adenosine A2A receptor antagonists and other antidepressants)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)
CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.




CM 2
CRN 75-75-2
CMF C H4 O3 S




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L16 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:74686 CAPLUS
DOCUMENT NUMBER: 142:298058
TITLE: Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors
AUTHOR(S): Boot, John; Cases, Manuel; Clark, Barry P.; Findlay, Jeremy; Gallagher, Peter T.; Hayhurst, Lorna; Man, Teresa; Montalbetti, Christian; Rathmell, Richard E.; Rudyk, Helene; Walter, Magnus W.; Wharton, Maria; Wood, Virginia
CORPORATE SOURCE: Lilly Research Centre, Eli Lilly & Co. Ltd, Surrey, GU20 6PH, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 699-703
CODEN: BMCLB; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:298058
AB Novel arylthiomethyl morpholines are potent selective norepinephrine reuptake inhibitors (NERIs) and dual serotonin/norepinephrine reuptake inhibitors (SRI/NERIs). The target compds. were prepared using a stereochem. versatile synthesis featuring an aldol condensation as the key step. One enantiomer of the 2-methoxy-substituted analog was found to be a potent and selective norepinephrine reuptake inhibitor, whereas the opposite enantiomer was a potent dual serotonin/norepinephrine reuptake inhibitor.
IT 667876-44-0P 668470-66-4P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (stereoselective preparation of (arylthiomethyl)morpholines as selective norepinephrine reuptake inhibitors and dual serotonin/norepinephrine reuptake inhibitors)
RN 667876-44-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-, (2R)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 668470-66-4 CAPLUS
CN Morpholine, 2-[(S)-[(2-methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




IT 667876-74-6P 667876-87-1P 847740-82-3P
 847740-83-4P 847740-84-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (stereoselective preparation of (arylthiomethyl)morpholines as selective norepinephrine reuptake inhibitors and dual serotonin/norepinephrine reuptake inhibitors)
 RN 667876-74-6 CAPLUS
 CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667876-87-1 CAPLUS
 CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 847740-82-3 CAPLUS
 CN Morpholine, 2-[(R)-phenyl(phenylthio)methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

ACCESSION NUMBER: 2004:1036891 CAPLUS
 DOCUMENT NUMBER: 142:16841
 TITLE: Treatment of emotional dysregulation
 INVENTOR(S): Allen, Albert John; Cloutier, Kathleen Ann; Michelson, David; Reimherr, Frederick William
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 155 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103356	A2	20041202	WO 2004-US13005	20040511
WO 2004103356	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-470752P P 20030515


OTHER SOURCE(S): MARPAT 142:16841
 AB Provided is a method of treating emotional dysregulation comprising administering to a patient in need of such treatment a selective norepinephrine reuptake inhibitor.

IT 668470-57-3P 668470-59-5P 668470-61-9P
 668470-69-1P 668470-92-7P 668470-94-8P
 668470-99-3P 800407-96-9P 800407-97-0P
 800407-98-1P 800407-99-2P 800408-00-8P
 800408-01-9P 800408-02-0P 800408-03-1P
 800408-04-2P 800408-05-3P 800408-06-4P
 800408-07-5P 800408-08-6P 800408-09-7P
 800408-10-0P 800408-11-1P 800408-12-2P
 800408-13-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (treatment of emotional dysregulation)


RN 668470-57-3 CAPLUS
 CN Morpholine, 2-[(S)-[(2-methylthio)phenyl]thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847740-83-4 CAPLUS
 CN Morpholine, 2-[(R)-[(3-methylphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 847740-84-5 CAPLUS
 CN Morpholine, 2-[(R)-[(4-methylphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 668470-59-5 CAPLUS
 CN Morpholine, 2-[(S)-[(2-(1-methylethyl)phenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-61-9 CAPLUS
 CN Morpholine, 2-[(S)-[(1,1'-biphenyl)-2-ylthio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-69-1 CAPLUS
 CN Morpholine, 4-(phenylmethyl)-2-[(S)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-93-7 CAPLUS
 CN Morpholine, 2-[(S)-[(2-fluorophenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-94-8 CAPLUS
CN Morphinoline, 2-[(S)-[2-ethylphenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-99-3 CAPLUS
CN Morphinoline, 4-(phenylmethyl)-2-[(S)-phenyl[(2-propylphenyl)thio]methyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800407-96-9 CAPLUS
CN Morphinoline, 2-[(R)-[2-fluorophenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800407-97-0 CAPLUS
CN Morphinoline, 2-[(R)-[2-ethylphenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 800408-02-0 CAPLUS
CN Morphinoline, 4-(phenylmethyl)-2-[(S)-phenyl[(2-trifluoromethoxyphenyl)thio]methyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-03-1 CAPLUS
CN Morphinoline, 2-[(S)-[2-methylphenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-04-2 CAPLUS
CN Morphinoline, 2-[(R)-[2-methylphenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-05-3 CAPLUS
CN Morphinoline, 4-(phenylmethyl)-2-[(R)-phenyl[(2-propylphenyl)thio]methyl]-, (2R)-(9CI) (CA INDEX NAME)




RN 800407-98-1 CAPLUS
CN Morphinoline, 2-[(S)-[2-methoxyphenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800407-99-2 CAPLUS
CN Morphinoline, 2-[(R)-[2-methoxyphenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-00-8 CAPLUS
CN Morphinoline, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-01-9 CAPLUS
CN Morphinoline, 2-[(R)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-06-4 CAPLUS
CN Benzoic acid, 2-[(S)-phenyl[(2S)-4-(phenylmethyl)-2-morpholinyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-07-5 CAPLUS
CN Benzoic acid, 2-[(R)-phenyl[(2R)-4-(phenylmethyl)-2-morpholinyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-08-6 CAPLUS
CN Morphinoline, 2-[(S)-[3-fluorophenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-09-7 CAPLUS
CN Morpholine, 2-[(R)-(3-fluorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl-4-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800408-10-0 CAPLUS
CN Morpholine, 2-[(R)-(4-chlorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl-4-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800408-11-1 CAPLUS
CN Morpholine, 2-[(R)-(4-chlorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl-4-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


(treatment of emotional dysregulation)
RN 668470-56-2 CAPLUS
CN Morpholine, 2-[(S)-phenyl][2-(trifluoromethyl)phenyl]thio]methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-63-1 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-64-2 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-ethylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-66-4 CAPLUS
CN Morpholine, 2-[(S)-[2-(methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 800408-12-2 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-fluorophenyl)][2-(methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800408-13-3 CAPLUS
CN Morpholine, 2-[(R)-[2-(2-fluorophenyl)][2-(methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 668470-56-2P 668470-63-1P 668470-64-2P
668470-66-4P 668470-67-5P 668470-69-7P
668470-70-0P 668470-71-1P 668470-72-2P
668470-74-4P 668470-76-6P 668470-78-8P
668470-88-0P
RL: SPN (Synthetic preparation); PREP (Preparation)




RN 668470-67-5 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-69-7 CAPLUS
CN Morpholine, 2-[(S)-phenyl][2-(trifluoromethoxy)phenyl]thio]methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-70-0 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-methylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-71-1 CAPLUS
CN Morpholine, 2-[(S)-phenyl][2-(propylphenyl)thio]methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-72-2 CAPLUS
 CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-74-4 CAPLUS
 CN Morpholine, 2-[(S)-(3-fluorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl
]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-76-6 CAPLUS
 CN Morpholine, 2-[(S)-(4-chlorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl
]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-78-8 CAPLUS
 CN Morpholine, 2-[(S)-(2-fluorophenyl)][2-(methoxyphenyl)thio]methyl]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-88-0 CAPLUS
 CN Morpholine, 4-[(1R)-1-phenylethyl]-2-[(R)-phenyl][2-(trifluoromethyl)phenyl]thio]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:703453 CAPLUS
 DOCUMENT NUMBER: 141:388520
 TITLE: Studies on the analgesic effects of antidepressants
 AUTHOR(S): Suciu, R.; Monea, Marioara
 CORPORATE SOURCE: Spitalul Clinic Judetean Targu-Mures, Tirgu-Mures,
 Rom.
 SOURCE: Revista de Medicina si Farmacie (2003), 49(2),
 118-124
 CODEN: RMFED7; ISSN: 1221-2229
 PUBLISHER: Universitatea de Medicina si Farmacie din Targu-Mures
 DOCUMENT TYPE: Journal
 LANGUAGE: Romanian

AB The effect of noradrenaline and serotonin on pain perception using
 anti-depressants like sertraline (selective serotonin reuptake
 inhibitor),
 tianeptine (selective serotonin reuptake accelerator) and reboxetine
 (selective noradrenaline reuptake inhibitor) is determined. The
 experiment was
 carried out on 5 groups of 8 rats each: group 1: placebo, group 2:
 reboxetine, group 3: reboxetine combined with naloxone, group 4 :
 tianeptine, group 5: sertraline. To test the analgesic effect of these
 drugs it was used the hot plate test and tail-flick test. The analgesic
 effect of reboxetine, tianeptine and sertraline became evident in 20 min
 after being administrated (p<0.05) in both hot plate and tail flick
 tests.

The analgesic effect of reboxetine was antagonized by naloxone (p<0.05).
 This means that the endogenous opioid system might play a role in the
 analgesic effect of these drugs. The fact that both tianeptine and
 sertraline have an analgesic effect, although they have opposite

mechanism
 of action might rise some questions about how serotonin really modulates
 pain but also the role of serotonin in depression.

IT 98769-84-7, Edronax
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (analgesic effects of antidepressants)


RN 98769-84-7 CAPLUS
 CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-,
 methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8

CMF C19 H23 N O3

Relative stereochemistry.




CM 2

CRN 75-75-2



L16 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:634561 CAPLUS
 DOCUMENT NUMBER: 141:288417
 TITLE: Pharmacokinetics, interaction potential, and therapeutic drug monitoring of modern antidepressants
 AUTHOR(S): Haertter, Sebastian
 CORPORATE SOURCE: Psychiatrische Klinik und Poliklinik, Klinikum der Johannes Gutenberg-Universitaet Mainz, Mainz, D-55131, Germany
 SOURCE: Pharmazie in Unserer Zeit (2004), 33(4), 296-303
 CODEN: PHUZBI; ISSN: 0048-3664
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: German
 AB A review is given on some pharmacokinetic characteristics of modern antidepressants. Pharmacokinetics, metabolism, and interaction with other drugs are discussed. Sense and advantages of the therapeutic drug monitoring were evaluated. Citalopram, mirtazapine, reboxetine, sertraline, and venlafaxine are considered.
 IT 98769-84-7, Edronax
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacokinetics, interaction potential, and therapeutic drug monitoring of modern antidepressants)
 RN 98769-84-7 CAPLUS
 CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)
 CM 1
 CRN 71620-89-8
 CMF C19 H23 N O3

Relative stereochemistry.



CM 2
 CRN 75-75-2
 CMF C H4 O3 S




REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS

L16 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:182854 CAPLUS
 DOCUMENT NUMBER: 140:235726
 TITLE: Preparation of benzyl morpholine derivatives capable of inhibiting serotonin and norepinephrine reuptake
 INVENTOR(S): Clark, Barry Peter; Gallagher, Peter Thaddeus; Haughton, Helen Louise
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018440	A1	20040304	WO 2003-US23268	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003261245	A1	20040311	AU 2003-261245	20030818
EP 1546123	A1	20050629	EP 2003-792992	20030818
EP 1546123	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 327982	T	20060615	AT 2003-792992	20030818
US 2006052377	A1	20060309	US 2003-524798	20050217
PRIORITY APPLN. INFO.:			GB 2002-19685	A 20020823
			US 2002-415327P	P 20021001
			WO 2003-US23268	W 20030818


OTHER SOURCE(S): CASREACT 140:235726; MARPAT 140:235726
 GI



L16 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
 FORMAT

L16 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AB Title compds. I [Ar = (un)substituted Ph optionally substituted with 1-5 substituents selected from alkyl, alkoxy, alkylthio, halo, or (un)substituted phenyl; X = (un)substituted Ph optionally substituted with 1-5 substituents selected from alkyl, alkoxy, or halo; R1 = H or alkyl; R = independently H or alkyl; each mentioned alkyl may be optionally substituted with one or more halo atoms] and pharmaceutically acceptable salts thereof are prepared and disclosed as inhibitors of serotonin and norepinephrine reuptake. Thus, e.g., II was prepared by condensation of 4-benzyl-2-cyanomorpholine with 4-bromoanisole to provide intermediate [4-methoxyphenyl][4-benzylmorpholin-2-yl]methanone which underwent subsequent reduction, substitution with 2,2'-dimethoxydiphenyldisulfide, debenzoylation and resolution via chiral chromatog. to provide II which was converted to its hydrochloride salt. I have been found to exhibit a Ki value less than 100nM at the serotonin transporter and a Ki value less than 100nM at the norepinephrine transporter as determined by scintillation proximity assays.
 IT 667876-41-7P
 RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation) (crystal structure; preparation of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)
 RN 667876-41-7 CAPLUS
 CN Morpholine, 2-[(S)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 667876-96-2P
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent) (intermediate; preparation of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)
 RN 667876-96-2 CAPLUS
 CN Morpholine, 2-[(R)-(4-chlorophenyl)[(2-methoxyphenyl)thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 667876-57-5P 667876-61-1P 667876-63-3P
667876-64-4P 667876-68-8P 667876-71-3P
667876-73-5P 667876-80-4P 667876-84-8P
667876-86-0P 667876-88-2P 667876-94-0P
667876-95-1P 667877-01-2P 667877-02-3P
667877-06-7P 667877-07-8P 667877-10-3P
667877-15-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of benzyl morpholine derivs. as selective
inhibitors of serotonin and norepinephrine reuptake)


RN 667876-57-5 CAPLUS
CN Morpholine, 2-[(R)-(4-methoxyphenyl)thio]methyl-4-
(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-61-1 CAPLUS
CN Morpholine, 2-[(R)-(2-fluorophenyl)thio]methyl-4-
(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-71-3 CAPLUS
CN Morpholine, 2-[(R)-(2-chlorophenyl)thio]phenylmethyl-4-(phenylmethyl)-,
(2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 667876-73-5 CAPLUS
CN Morpholine, 2-[(R)-(2-methylphenyl)thio]phenylmethyl-4-(phenylmethyl)-,
(2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-80-4 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenyl]thio-
(trifluoromethyl)phenylthio]methyl-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-63-3 CAPLUS
CN Morpholine, 2-[(R)-[(2,5-dichlorophenyl)thio]phenylmethyl]-4-
(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667876-64-4 CAPLUS
CN Morpholine, 2-[(R)-[(2,6-dichlorophenyl)thio]phenylmethyl]-4-
(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667876-68-8 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]methyl]-4-
(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 667876-84-8 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-,
(2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-86-0 CAPLUS
CN Morpholine,
2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-,
(2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-88-2 CAPLUS
CN Morpholine, 2-[(R)-[(2-methylthio)phenyl]thio]phenylmethyl-4-
(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-94-0 CAPLUS
CN Morpholine, 2-[(R)-(4-chlorophenyl)thio]methyl-4-
(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667876-95-1 CAPLUS
CN Morpholine, 2-[(R)-(4-chlorophenyl)[(2-methoxyphenyl)thio]methyl]-, hydrochloride, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RN 667877-01-2 CAPLUS
CN Morpholine, 2-[(R)-(3-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667877-02-3 CAPLUS
CN Morpholine, 2-[(R)-(3-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)



● HCl


RN 667877-10-3 CAPLUS
CN Morpholine, 2-[(R)-(2-chlorophenyl)[(2-methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667877-15-8 CAPLUS
CN Morpholine, 2-[(R)-(4-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 667876-62-2P 667876-69-9P 667876-72-4P
667876-74-6P 667876-81-5P 667876-85-9P


Relative stereochemistry.



● HCl

RN 667877-06-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenyl)thio](3-fluorophenyl)methyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667877-07-8 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenyl)thio](3-fluorophenyl)methyl)-, hydrochloride, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

667876-87-1P 667876-89-3P 667877-03-4P
667877-09-0P 667877-11-4P 667877-16-9P
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process) (prepn. of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)


RN 667876-62-2 CAPLUS
CN Morpholine, 2-[(R)-(2-fluorophenyl)[(2-methoxyphenyl)thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-69-9 CAPLUS
CN Morpholine, 2-[(R)-(2-methoxyphenyl)thio](4-methylphenyl)methyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-72-4 CAPLUS
CN Morpholine, 2-[(R)-(2-chlorophenyl)thio]phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-74-6 CAPLUS
CN Morpholine, 2-[(R)-(2-methylphenyl)thio]phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-81-5 CAPLUS
CN Morpholine, 2-[(R)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-85-9 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethylphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-87-1 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-89-3 CAPLUS
CN Morpholine, 2-[(R)-[(2-methylthio)phenyl]thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)



RN 667877-16-9 CAPLUS
CN Morpholine, 2-[(R)-[(4-fluorophenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 667876-40-6P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)


RN 667876-40-6 CAPLUS
CN Morpholine, 2-[(R)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

Relative stereochemistry.




RN 667877-03-4 CAPLUS
CN Morpholine, 2-[(R)-[(3-fluorophenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667877-09-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethoxyphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667877-11-4 CAPLUS
CN Morpholine, 2-[(R)-[(2-chlorophenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

667876-44-0P 667876-50-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compd.; prepn. of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)


RN 667876-27-9 CAPLUS
CN Morpholine, 2-[(R)-[(2-fluorophenyl)thio]phenylmethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667876-37-1 CAPLUS
CN Morpholine, 2-[(R)-[(2-chlorophenyl)thio]phenylmethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667876-42-8 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethylphenyl)thio]phenylmethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667876-44-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667876-50-8 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethoxyphenyl)thio](3-fluorophenyl)methyl]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 667876-26-8P 667876-36-0P 667876-39-3P
667876-43-9P 667876-45-1P 667876-46-2P
667876-47-3P 667876-48-4P 667876-49-5P
667876-51-9P 667876-54-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound: preparation of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)

RN 667876-26-8 CAPLUS
CN Morpholine, 2-[(R)-[(4-methoxyphenyl)thio]methyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 667876-43-9 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethylphenyl)thio]phenylmethyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-45-1 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 667876-46-2 CAPLUS
CN Morpholine, 2-[(R)-[(2-methylthio)phenyl]thio]phenylmethyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



● HCl

RN 667876-36-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio](4-methylphenyl)methyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-39-3 CAPLUS
CN Morpholine, 2-[(R)-[(2-methylphenyl)thio]phenylmethyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-47-3 CAPLUS
CN Morpholine, 2-[(R)-[(4-chlorophenyl)thio]phenylmethyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-48-4 CAPLUS
CN Morpholine, 2-[(R)-[(3-fluorophenyl)thio]phenylmethyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-49-5 CAPLUS
CN Morpholine, 2-[(R)-[(2-ethoxyphenyl)thio](3-fluorophenyl)methyl]-, hydrochloride, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-51-9 CAPLUS
CN Morpholine, 2-[(R)-[(2-chlorophenyl)thio](3-fluorophenyl)methyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 667876-54-2 CAPLUS
CN Morpholine, 2-[(R)-[(4-fluorophenyl)thio](2-methoxyphenyl)methyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L16 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)

RN 667876-28-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-fluorophenyl)thio](2-methoxyphenyl)methyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-30-4 CAPLUS
CN Morpholine, 2-[(R)-[(2,5-dichlorophenyl)thio]phenylmethyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-34-8 CAPLUS
CN Morpholine, 2-[(R)-[(2,6-dichlorophenyl)thio]phenylmethyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 667876-32-6P 667876-52-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compound; preparation of benzyl morpholine derivs. as selective inhibitors of serotonin and norepinephrine reuptake)


RN 667876-32-6 CAPLUS
CN Morpholine, 2-[(R)-[(2,5-dichlorophenyl)thio]phenylmethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667876-52-0 CAPLUS
CN Morpholine, 2-[(R)-[(2-chloro-6-methylphenyl)thio]phenylmethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 667876-28-0P 667876-30-4P 667876-34-8P
667876-38-2P 667876-53-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU



● HCl

RN 667876-38-2 CAPLUS
CN Morpholine, 2-[(R)-[(2-chlorophenyl)thio]phenylmethyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 667876-53-1 CAPLUS
CN Morpholine, 2-[(R)-[(2-chloro-6-methylphenyl)thio]phenylmethyl]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:182714 CAPLUS
 DOCUMENT NUMBER: 140:235724
 TITLE: Preparation of benzyl morpholine derivatives capable of selectively inhibiting norepinephrine reuptake
 INVENTOR(S): Walter, Magnus Wilhelm; Clark, Barry Peter; Gallagher,
 Peter Thaddeus; Haughton, Helen Louise; Rudyk, Helene Catherine Eugenie
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017977	A2	20040304	WO 2003-US23269	20030818
WO 2004017977	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TG				
AU 2003269923	A1	20040311	AU 2003-269923	20030818
EP 1534291	A2	20050601	EP 2003-751812	20030818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006035894	A1	20060216	US 2005-524650	20050217
PRIORITY APPLN. INFO.: GB 2002-19690 A 20020823				
US 2002-415328P P 20021001				
WO 2003-US23269 W 20030818				


OTHER SOURCE(S): MARPAT 140:235724
 GI



AB Title compds. I [A = S or O; Ar = (un)substituted Ph optionally


L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Morpholine, 2-[(R)-[(2-methoxyphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-88-0 CAPLUS
 CN Morpholine, 4-[(1R)-1-phenylethyl]-2-[(R)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-89-1 CAPLUS
 CN Morpholine, 4-(phenylmethyl)-2-[(S)-phenyl[(2-(trifluoromethyl)phenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-90-4 CAPLUS
 CN Morpholine, 2-[(S)-[(2-(methylthio)phenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 substituted with 1-5 substituents selected from alkyl, alkoxy, alkylthio, halo, etc.; X = (un)substituted Ph optionally substituted with 1-5 substituents selected from halo, alkyl, alkoxy, cycloalkyl, etc.; R1 = H or alkyl; R = independently H or alkyl; each mentioned alkyl may be optionally substituted with one or more halo atoms; with provisions that when A = O, X = an alkyl group, a cycloalkyl group or cycloalkylmethyl group and pharmaceutically acceptable salts thereof are prepd. and disclosed as inhibitors of serotonin and norepinephrine reuptake. Thus, e.g., II was prepd. via substitution of


(2S)-2-[(R)-bromo(phenyl)methyl]-4-(phenylmethyl)morpholine (prepn. given) with 2-trifluoromethylthiophenol with subsequent debenzoylation. I have been found to exhibit a Ki value less than 500nM at the norepinephrine transporter as detd. by scintillation proximity assays. In addn., I have been found to selectively inhibit norepinephrine transporter relative to the serotonin and dopamine transporters by a factor of at least five.

IT 667876-61-1P 667876-73-5P 667876-86-0P
 668470-88-0P 668470-89-1P 668470-90-4P
 668470-91-5P 668470-92-6P 668470-93-7P
 668470-94-8P 668470-95-9P 668470-97-1P
 668470-99-3P 668471-00-5P 668471-02-1P
 668471-04-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of benzyl morpholine derivs. as selective inhibitors of norepinephrine reuptake)


RN 667876-61-1 CAPLUS
 CN Morpholine, 2-[(R)-[(2-fluorophenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667876-73-5 CAPLUS
 CN Morpholine, 2-[(R)-[(2-methylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 667876-86-0 CAPLUS


L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 668470-91-5 CAPLUS
 CN Morpholine, 2-[(S)-[(2-(1-methylethyl)phenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-92-6 CAPLUS
 CN Morpholine, 2-[(S)-[(1,1'-biphenyl)-2-ylthio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-93-7 CAPLUS
 CN Morpholine, 2-[(S)-[(2-fluorophenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-94-8 CAPLUS
 CN Morpholine, 2-[(S)-[(2-ethylphenyl)thio]phenylmethyl]-4-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 668470-95-9 CAPLUS
CN Morpholine, 2-[(R)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-4-(phenylmethyl)-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-97-1 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(R)-phenyl[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 668470-99-3 CAPLUS
CN Morpholine, 4-(phenylmethyl)-2-[(S)-phenyl[2-(propylphenyl)thio]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668471-00-9 CAPLUS
CN Benzoic acid, 2-[(R)-phenyl[2-(4-(phenylmethyl)-2-morpholinyl)methyl]thio]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 667876-62-2 CAPLUS
CN Morpholine, 2-[(R)-[2-(2-fluorophenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 667876-74-6 CAPLUS
CN Morpholine, 2-[(R)-[2-(2-methylphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 667876-85-9 CAPLUS
CN Morpholine, 2-[(R)-[2-(2-ethylphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 667876-87-1 CAPLUS
CN Morpholine, 2-[(R)-[2-(2-methoxyphenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668471-02-1 CAPLUS
CN Morpholine, 2-[(R)-[2-(3-fluorophenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-04-3 CAPLUS
CN Morpholine, 2-[(R)-[2-(4-chlorophenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 667876-62-2P 667876-74-6P 667876-85-9P
667876-87-1P 668470-96-OP 668470-98-2P
668471-01-OP 668471-03-2P 668471-05-4P
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation of benzyl morpholine derivs. as selective inhibitors of norepinephrine reuptake)

L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668470-96-0 CAPLUS
CN Morpholine, 2-[(R)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668470-98-2 CAPLUS
CN Morpholine, 2-[(R)-phenyl[2-(trifluoromethoxy)phenyl]thio]methyl]-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 668471-01-0 CAPLUS
CN Benzoic acid, 2-[(R)-[2-(2-morpholinyl)phenylmethyl]thio]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 668471-03-2 CAPLUS
CN Morpholine, 2-[(R)-[2-(3-fluorophenyl)thio]phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)


L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
1-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668471-05-4 CAPLUS
CN Morpholine, 2-[(R)-(4-chlorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl
1-, (2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 668470-64-2P 668470-67-5P 668470-72-2P
668470-74-4P 668470-76-6P 668470-78-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT
(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
(Uses)
(target compound; preparation of benzyl morpholine derivs. as
selective
inhibitors of norepinephrine reuptake)
RN 668470-64-2 CAPLUS
CN Morpholine, 2-[(S)-[(2-ethylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668470-78-8 CAPLUS
CN Morpholine, 2-[(S)-(2-fluorophenyl)][2-(methoxyphenyl)thio]methyl-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 668470-66-4P 668470-69-7P 668470-70-0P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(target compound; preparation of benzyl morpholine derivs. as
selective
inhibitors of norepinephrine reuptake)
RN 668470-66-4 CAPLUS
CN Morpholine, 2-[(S)-[(2-methoxyphenyl)thio]phenylmethyl]-, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 668470-69-7 CAPLUS
CN Morpholine, 2-[(S)-phenyl][2-(trifluoromethoxy)phenyl]thio]methyl-, (2S)-
(9CI) (CA INDEX NAME)

L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 668470-67-5 CAPLUS
CN Morpholine, 2-[(S)-[(2-(1-methylethoxy)phenyl)thio]phenylmethyl]-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-72-2 CAPLUS
CN Benzoic acid, 2-[(S)-(2S)-2-morpholinylphenylmethyl]thio]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-74-4 CAPLUS
CN Morpholine, 2-[(S)-(3-fluorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl
1-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668470-76-6 CAPLUS
CN Morpholine, 2-[(S)-(4-chlorophenyl)][2-(trifluoromethyl)phenyl]thio]methyl
1-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L16 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 668470-70-0 CAPLUS
CN Morpholine, 2-[(S)-[(2-methylphenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




IT 668470-57-3P 668470-59-5P 668470-61-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of benzyl morpholine derivs. as
selective
inhibitors of norepinephrine reuptake)
RN 668470-57-3 CAPLUS
CN Morpholine, 2-[(S)-[(2-methylthio)phenyl]thio]phenylmethyl]-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-59-5 CAPLUS
CN Morpholine, 2-[(S)-[(2-(1-methylethyl)phenyl)thio]phenylmethyl]-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-61-9 CAPLUS
CN Morpholine, 2-[(S)-([1,1'-biphenyl]-2-ylthio)phenylmethyl]-, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 668470-56-2P 668470-58-4P 668470-60-8P
668470-62-0P 668470-63-1P 668470-65-3P
668470-68-6P 668470-71-1P 668470-73-3P
668470-75-5P 668470-77-7P 668470-79-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(target compound; preparation of benzyl morpholine derivs. as
selective inhibitors of norepinephrine reuptake)


RN 668470-56-2 CAPLUS
CN Morpholine, 2-[(S)-phenyl[[2-(trifluoromethyl)phenyl]thio]methyl]-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668470-58-4 CAPLUS
CN Morpholine, 2-[(S)-[2-(methylthio)phenyl]thio]phenylmethyl]-,
hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668470-65-3 CAPLUS
CN Morpholine, 2-[(S)-[2-ethylphenyl]thio]phenylmethyl]-, hydrochloride,
(2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-68-6 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethoxy)phenyl]thio]phenylmethyl]-,
hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-71-1 CAPLUS
CN Morpholine, 2-[(S)-phenyl[[2-(propylphenyl)thio]methyl]-, (2S)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-60-8 CAPLUS
CN Morpholine, 2-[(S)-[2-(1-methylethyl)phenyl]thio]phenylmethyl]-,
hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 668470-62-0 CAPLUS
CN Morpholine, 2-[(S)-[2-(2-fluorophenyl)thio]phenylmethyl]-,
hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-63-1 CAPLUS
CN Morpholine, 2-[(S)-[2-(3-fluorophenyl)thio]phenylmethyl]-, (2S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 668470-73-3 CAPLUS
CN Benzoic acid, 2-[(S)-[2-(2-morpholinylphenylmethyl)thio]-, methyl
ester,
hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 668470-75-5 CAPLUS
CN Morpholine,
2-[(S)-[2-(3-fluorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl
]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 668470-77-7 CAPLUS
CN Morpholine,
2-[(S)-[2-(4-chlorophenyl)[2-(trifluoromethyl)phenyl]thio]methyl
]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)



● HCl

RN 668470-79-9 CAPLUS
CN Morpholine, 2-[(S)-(2-(4-fluorophenyl)[(2-methoxyphenyl)thio]methyl)-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L16 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
mass parts Verapamil HCl and 50 mass parts Eudragit L 100-55, then 160 g of the ground hot melt compd. was mixed with 230 g lactose, 180 g Avicel PH 102, 30 g Explotab and 3 g magnesium stearate and pressed to tablets.
IT 98769-84-7, Reboksetine mesylate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (melt extrusion consisting of salts of active ingredients and (meth)acrylate copolymer)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



L16 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:696718 CAPLUS
DOCUMENT NUMBER: 139:219346
TITLE: Melt extrusion consisting of salts of active ingredients and (meth)acrylate copolymer
INVENTOR(S): Peterreit, Hans-Ulrich; Meier, Christian; Gryczke, Andreas
PATENT ASSIGNEE(S): Roehm G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072083	A2	20030904	WO 2003-EP935	20030130
WO 2003072083	A3	20040408		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DE, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10208344	A1	20030904	DE 2002-10208344	20020227
CA 2474691	A1	20030904	CA 2003-2474691	20030130
AU 2003210196	A1	20030909	AU 2003-210196	20030130
EP 1478344	A2	20041124	EP 2003-742925	20030130
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003007995	A	20041207	BR 2003-7995	20030130
JP 2005526731	T	20050908	JP 2003-570829	20030130
US 2004253314	A1	20041216	US 2004-498829	20040624
PRIORITY APPL. INFO.:			DE 2002-10208344	A 20020227
			WO 2003-EP935	W 20030130

AB The invention relates to a method for producing active ingredient-containing granules or powders involving the following steps: (a) melting a mixture consisting of a pharmaceutically active ingredient and of a (meth)acrylate copolymer, which is comprised of 40-75 weight% of radically polymerized alkyl esters of acrylic acid or of methacrylic acid and can be comprised of 25-60 weight% (meth)acrylate monomers having an anionic group in the alkyl radical; (b) extruding the mixture, and; (c) comminuting the extrudate to form a granule or powder. The inventive method is characterized in that the active ingredient is the salt of an alkaline substance, and in that the pH value, which can be measured on the obtained powder or granule, is equal to or less than pH 7.0. The invention also relates to pharmaceutical dosage forms or precursors thereof, which can be produced using the inventive method. Thus a hot melt compound was prepared by coextruding

L16 ANSWER 26 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:356092 CAPLUS
DOCUMENT NUMBER: 138:353997
TITLE: Method for the preparation of aryl ethers
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1308443	A2	20030507	EP 2003-2146	19991223
EP 1308443	A3	20031001		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EP 1140788	A1	20011010	EP 1999-967557	19991223
EP 1140788	B1	20040225		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
IN 2005MN00168	A	20050923	IN 2005-MN168	20050304
PRIORITY APPL. INFO.:			US 1998-114092P	P 19981229
			EP 1999-967557	A3 19991223
			WO 1999-US30748	W 19991223
			IN 2001-MN483	A3 20010427

OTHER SOURCE(S): CASREACT 138:353997; MARPAT 138:353997
GI




AB Aryl ethers I (R, R1 = (un)substituted Ph) are prepared by epoxidn. of an alkenol RCH:CHCH2OH, epoxide cleavage with R1OH, amination N-chloroacetylation, cyclization, and reduction of the resulting morpholine with a reducing agent, such as BH3, DIBAL, (Me2CH)2AlH, or Na(MeOCH2CH2O)2AlH. Thus, reboksetine was prepared from trans-cinnamyl alc. and 2-EtOC6H4OH in 6 steps.
IT 98769-84-7P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of aryl ethers from alkenes via epoxides)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L16 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:353282 CAPLUS
DOCUMENT NUMBER: 136:350586
TITLE: The use of selective noradrenaline reuptake inhibitors
INVENTOR(S): for the treatment of tension-type headache
PATENT ASSIGNEE(S): Olesen, Jes; Jensen, Rigmar; Bendtsen, Lars
SOURCE: Head Explorer A.P.S., Den.
PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036125	A1	20020510	WO 2001-DK717	20011029
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002013830	A5	20020515	AU 2002-13830	20011029
EP 1333835	A1	20030813	EP 2001-982184	20011029
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004048860	A1	20040311	US 2003-415588	20030806
PRIORITY APPLN. INFO.:			DK 2000-1638	A 20001031
			US 2000-246736P	P 20001109
			WO 2001-DK717	W 20011029

OTHER SOURCE(S): MARPAT 136:350586
AB This invention relates to the use of selective noradrenaline reuptake inhibitors, in particular reboxetine, for the treatment of tension-type headache. Patients with chronic tension-type headache were treated with reboxetine as the methanesulfonate salt.
IT 98769-84-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of selective noradrenaline reuptake inhibitors for treatment of tension-type headache)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.

L16 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:771959 CAPLUS
DOCUMENT NUMBER: 136:236927
TITLE: Analysis of reboxetine, a novel antidepressant drug, in pharmaceutical tablets by capillary electrophoresis
electrophoresis and derivative spectrophotometry
AUTHOR(S): Raggi, M. A.; Bugamelli, F.; Sabbioni, C.; Ferranti, A.; Fanali, S.; Volterra, V.
CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of Bologna, Bologna, 40126, Italy
SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2002), 27(1-2), 209-215
CODEN: JPBADA. ISSN: 0731-7085
Elsevier Science B.V.
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The recent antidepressant drug reboxetine was quantified in pharmaceutical tablets by derivative spectrophotometry and capillary zone electrophoresis.
The feasible sample pretreatment consists of a single extraction with a pH 2.5 phosphate buffer, centrifugation and dilution. For the spectrophotometric assay, the 4th derivative of the absorbance was used which gave satisfactory results in terms of accuracy (mean recovery 99.7%) and precision (mean relative standard deviation 3.4%). The electrophoretic expts. were carried out using the shortest effective length of the capillary (8.5 cm) to obtain a very rapid separation of reboxetine and dibenzepine used as the internal standard. Using a pH 2.5, 50 mM phosphate buffer as the background electrolyte, each anal. lasted <2.5 min. Accuracy (101.3%) and precision (1.5%) were very good.
IT 98769-84-7, Davedax
RL: AMX (Analytical matrix); ANST (Analytical study)
(anal. of reboxetine, a novel antidepressant drug, in pharmaceutical tablets by capillary electrophoresis and derivative spectrophotometry)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

ACCESSION NUMBER: 2001:565626 CAPLUS
DOCUMENT NUMBER: 135:335263

TITLE: Direct separation of the enantiomers of reboxetine by liquid chromatography on different cellulose- and amylose-based chiral stationary phases
 Ficarra, R.; Calabro, M. L.; Tommasini, S.; Melardi, S.; Cutroneo, P.; Ficarra, P.
 CORPORATE SOURCE: Department of Pharmac-Biological Sciences, University of Catanzaro "Magna Graecia", Complesso „Nini Barbieri“, Catanzaro, 88021, Italy

SOURCE: Chromatographia (2001), 53(5/6), 261-265
 CODEN: CHRG7; ISSN: 0009-5893
 PUBLISHER: Friedrich Vieweg & Sohn Verlagsgesellschaft mbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Racemic reboxetine, (R,S)-2-[(R,S)-α-(2-ethoxyphenoxybenzyl)] morpholine methane sulfonate, is a mixture of the (R,R) and (S,S) enantiomers. Separation of the enantiomers of reboxetine by liquid chromatog. has been investigated on three chiral stationary phases - cellulose tris-(3,5-dimethylphenylcarbamate) (Chiralcel OD), cellulose tris-(phenylcarbamate) (Chiralcel OC), and amylose tris-(3,5-dimethylphenylcarbamate) (Chiralpak AD). On these stationary phases the resolution of the (R,R) and (S,S) enantiomers was highly dependent on mobile phase composition. When Chiralcel OD and OC were used, addition of diethylamine to the mobile phase greatly improved the separation of the enantiomers. On Chiralpak AD enantiosepn. was achieved without the use of additives. Solute-mobile phase-stationary phase interactions which might participate in the mechanism of enantio-recognition are discussed.

IT 98769-84-7
 RL: ANT (Analyte); ANST (Analytical study)
 (direct separation of enantiomers of reboxetine by liquid chromatog.

on different cellulose- and amylose-based chiral stationary phases)


RN 98769-84-7 CAPLUS

CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

ACCESSION NUMBER: 2001:489216 CAPLUS
DOCUMENT NUMBER: 135:81956

TITLE: Transdermal administration of reboxetine
 Hoeck, Ulla; Krailgard, Bo; Kristensen, Helle
 PATENT ASSIGNEE(S): Pharmacia AB, Swed.
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047503	A1	20010705	WO 2000-SE1972	20001012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1244431	A1	20021002	EP 2000-971947	20001012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			SE 1999-4750	A 19991223
			WO 2000-SE1972	W 20001012


AB A device for transdermal administration of reboxetine, optionally encompassing salts, prodrugs and metabolites thereof, to the use of reboxetine, optionally encompassing salts, prodrugs and metabolites thereof is disclosed. Also disclosed is a method for the manufacturing of a medicament to be administered transdermally, and methods of treating depression and/or symptoms associated with this condition and/or for treating addictive disorders and withdrawal syndromes, adjustment disorders, age-associated learning and mental disorders, anorexia nervosa, apathy, attention-deficit disorders due to general medical conditions, attention-deficit hyperactivity disorders, bipolar disorders, bulimia nervosa, chronic fatigue syndrome, conduct disorders, cyclothymic disorders, depression, dysthymic disorders, fibromyalgia and other somatoform disorders, stress incontinence, generalized anxiety disorders, inhalation disorders, an intoxication disorders, obesity, obsessive compulsive disorders and related spectrum disorders, oppositional defiant disorders, and panic disorder. The method also can be applied to treatment of peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, psychotic disorders, seasonal affective disorder, sleep disorder, social phobia, specific developmental disorders and selective serotonin reuptake inhibition (SSRI) "poop out" syndrome and symptoms associated with these conditions, and/or for obtaining an anti-reserpine and/or noradrenaline reuptake inhibiting effect by transdermal administration of reboxetine, optionally encompassing salts, prodrugs, and metabolites thereof.

IT 98769-84-7
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

L16 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Biological study); PROC (Process)
(transdermal administration of reboxetine for neuropsychiatric therapies)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1
CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2
CRN 75-75-2
CMF C H4 O3 S




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L16 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
polyethylene glycol 3350.
IT 98769-84-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES

(Uses)
(reboxetine sustained-release dosage forms)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1
CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2
CRN 75-75-2
CMF C H4 O3 S



L16 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:208079 CAPLUS
DOCUMENT NUMBER: 134:242664
TITLE: Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
INVENTOR(S): Seroff, Sylvia; Yam, Noyim; Ayer, Atul D.; Bhatt, Padmanabh; Desjardins, Michael A.; Lam, Andrew C.; Edgren, David E.; Nixon, Phillip R.
PATENT ASSIGNEE(S): Alza Corporation, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019337	A2	20010322	WO 2000-US25333	20000915
WO 2001019337	A3	20010809		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6387403	B1	20020514	US 2000-661976	20000914
CA 2384624	A1	20010322	CA 2000-2384624	20000915
EP 1216031	A2	20020626	EP 2000-963500	20000915
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
TW 233809	B	20050611	TW 2000-89118958	20000915
US 2002146453	A1	20021010	US 2002-87026	20020228
US 6630165	B2	20031007		
PRIORITY APPLN. INFO.:			US 1999-153997P	P 19990915
			US 2000-661976	A1 20000914
			WO 2000-US25333	W 20000915

AB Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concns. when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 h period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form. An osmotic dosage forms comprising a bilayer compressed core consisting of a drug layer containing reboxetine methanesulfonate and a push layer in the internal compartment for providing sustained-release of reboxetine were made, and coated with the semipermeable membrane composition containing cellulose acetate (CA 398-10) and

L16 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:31317 CAPLUS
DOCUMENT NUMBER: 134:105849
TITLE: Highly selective norepinephrine reuptake inhibitors and methods of using the same
INVENTOR(S): Wong, Erik H. F.; Ahmed, Saeeduddin; Marshall, Robert Clyde; McArthur, Robert; Taylor, Duncan P.;

Birgersson,
PATENT ASSIGNEE(S): Lars; Cetera, Pasquale
SOURCE: Pharmacia & Upjohn Company, USA
PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001973	A2	20010111	WO 2000-US17256	20000622
WO 2001001973	A3	20020117		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2375908	A1	20010111	CA 2000-2375908	20000622
CA 2375908	C	20060530		
CA 2532330	A1	20010111	CA 2000-2532330	20000622
CA 2543986	A1	20010111	CA 2000-2543986	20000622
AU 200056337	A	20010122	AU 2000-56337	20000622
AU 771258	B2	20040318		
EP 1196172	A2	20020417	EP 2000-941659	20000622
EP 1196172	B1	20060315		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
BR 2000012136	A	20020611	BR 2000-12136	20000622
HU 200201623	A2	20020928	HU 2002-1623	20000622
US 6465458	B1	20021015	US 2000-599213	20000622
JP 2003030450	T	20030128	JP 2001-507467	20000622
NZ 515885	A	20040827	NZ 2000-515885	20000622
EP 1459748	A1	20040922	EP 2004-13379	20000622
EP 1459748	B1	20050413		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EP 1459749	A1	20040922	EP 2004-13381	20000622
EP 1459749	B1	20051005		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EP 1459750	A1	20040922	EP 2004-13382	20000622
EP 1459750	B1	20050601		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EP 1459751	A1	20040922	EP 2004-13383	20000622
EP 1459751	B1	20050914		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			

L16 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

EP 1493442 A1 20050105 EP 2004-23888 20000622

EP 1493442 B1 20050928

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

EP 1500395 A1 20050126 EP 2004-25513 20000622

EP 1500395 B1 20060308

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

EP 1500396 A1 20050126 EP 2004-25514 20000622

EP 1500396 B1 20050928

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

AT 292971 T 20050415 AT 2004-13379 20000622

AT 296634 T 20050615 AT 2004-13382 20000622

CN 1660108 A 20050831 CN 2004-10104522 20000622

CN 1660109 A 20050831 CN 2004-10104523 20000622

CN 1660110 A 20050831 CN 2004-10104524 20000622

CN 1660111 A 20050831 CN 2004-10104525 20000622

AT 304358 T 20050915 AT 2004-13383 20000622

ES 2239311 T3 20050916 ES 2004-4013379 20000622

AT 305788 T 20051015 AT 2004-13381 20000622

AT 305306 T 20051015 AT 2004-23888 20000622

AT 305307 T 20051015 AT 2004-25514 20000622

ES 2242175 T3 20051101 ES 2004-4013382 20000622

PT 1459751 T 20051130 PT 2004-13383 20000622

NZ 533243 A 20051223 NZ 2000-533243 20000622

ES 2246485 T3 20060216 ES 2004-4013381 20000622

ES 2246487 T3 20060216 ES 2004-4023888 20000622

ES 2246488 T3 20060216 ES 2004-4025514 20000622

EP 1629843 A2 20060301 EP 2005-111705 20000622

EP 1629843 A3 20060315

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

ES 2247572 T3 20060301 ES 2004-4013383 20000622

EP 1632234 A2 20060308 EP 2005-111704 20000622

EP 1632234 A3 20060315

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

EP 1632235 A2 20060308 EP 2005-111706 20000622

EP 1632235 A3 20060614

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

AT 319453 T 20060315 AT 2004-25513 20000622

AT 320257 T 20060315 AT 2004-25513 20000622

PT 1196172 T 20060531 PT 2000-941659 20000622

ES 2258010 T3 20060816 ES 2000-941659 20000622

ES 2258251 T3 20060816 ES 2004-4025513 20000622

CN 1820754 A 20060823 CN 2005-10136906 20000622

NZ 542816 A 20061222 NZ 2000-542816 20000622

TW 245631 B 20051221 TW 2000-8913086 20000905

US 2002061910 A1 20020523 US 2001-20261 20011214

US 6703389 B2 20040309

ZA 2001010325 A 20030314 ZA 2001-10325 20011214

NO 2001006406 A 20020219 NO 2001-6406 20011228

US 2002086864 A1 20020704 US 2002-37344 20020104

US 6610690 B2 20030826

US 2002128173 A1 20020912 US 2002-99334 20020104

US 6642235 B2 20031104

L16 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

potent than racemic reboxetine in respect to inhibiting the reuptake of norepinephrine in rats. The selectivity of Ki of serotonin/norepinephrine for (S,S)-reboxetine and racemic reboxetine was 12,770 and 81, resp.

IT 98819-77-3

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (comps. containing highly selective norepinephrine reuptake inhibitors for treatment of psychiatric and other diseases)

RN 98819-77-3 CAPLUS


CN Morpholine, 2-[(S)-(2-ethoxyphenoxy)phenylmethyl]-, (2S)-, methanesulfonate (SCI) (CA INDEX NAME)

CM 1

CRN 98819-76-2

CMF C19 H23 N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 75-75-2

CMF C H4 O3 S



L16 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US 2003040464 A1 20030227 US 2002-255450 20020926

HK 1049630 A1 20050923 HK 2003-101844 20030314

US 2004059925 A1 20040325 US 2003-669611 20030924

US 2004147614 A1 20040729 US 2004-758864 20040116

AU 2004202096 A1 20040610 AU 2004-202096 20040518

AU 2005220235 A1 20051027 AU 2005-220235 20051007

US 2006128705 A1 20060615 US 2006-349373 20060207

US 2006135520 A1 20060622 US 2006-349022 20060207

US 2006135521 A1 20060622 US 2006-349331 20060207

US 2006142289 A1 20060629 US 2006-348948 20060207

JP 2006143749 A 20060608 JP 2006-45459 20060222

US 2006264436 A1 20061123 US 2006-460775 20060728

JP 2006321815 A 20061130 JP 2006-210418 20060802

PRIORITY APPLN. INFO.: US 1999-141968P P 19990701

US 1999-144131P P 19990716

US 1999-158256P P 19991006

US 1999-170381P P 19991213

US 1999-141986P P 19990701

CA 2000-2375908 A3 20000622

CN 2000-808485 A3 20000622

CN 2004-10104522 A3 20000622

EP 2000-941659 A3 20000622

JP 2001-507467 A3 20000622

US 2000-599213 A 20000622

WO 2000-US17256 W 20000622

US 2002-255450 A3 20020926

US 2004-758864 A3 20040116

AU 2004-202096 A3 20040518

AB Methods and comps. for treating humans suffering from, or preventing a human from suffering, a physiol. or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The comps. comprise a compound having a high pharmacol. selectivity with respect to norepinephrine reuptake sites compared to serotonin reuptake sites. The pharmacol. selectivity of serotonin (Ki)/norepinephrine (Ki) is at least about 5000, preferably about 10,000-12,000. Examples of such comps. include reboxetine in an amount of 6-10 mg/day, and more preferably optically pure (S,S) enantiomer substantially free of (R,R) reboxetine. The methods generally include administration of a therapeutic amount of such comps. Preparation of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiol. or psychiatric disease, disorder, or condition are also disclosed. For example, (S,S)-reboxetine was about 5-8 fold more

L16 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:457014 CAPLUS

DOCUMENT NUMBER: 133:89532

TITLE: Process for the preparation of aryl ether diastereomers

INVENTOR(S): Henegar, Kevin E.; Mancini, Sarah Elizabeth; Maisto, Keith Douglas

PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA

SOURCE: PCT Int. Appl., 53 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039072	A1	20000706	WO 1999-US30748	19991223
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PG, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2349619	A1	20000706	CA 1999-2349619	19991223
EP 1140788	A1	20011010	EP 1999-967557	19991223
EP 1140788	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916615	A	20011023	BR 1999-16615	19991223
TR 200101885	T2	20020121	TR 2001-200101885	19991223
US 6376711	B1	20020423	US 1999-469429	19991223
JP 2002533430	T	20021008	JP 2000-590985	19991223
NZ 511452	A	20021126	NZ 1999-511452	19991223
HU 200202144	A2	20021128	HU 2002-2144	19991223
AU 764492	B2	20030821	AU 2000-23819	19991223
AT 260238	T	20040315	AT 1999-967557	19991223
PT 1140788	T	20040730	PT 1999-967557	19991223
ES 2214060	T3	20040901	ES 1999-967557	19991223
CN 1532194	A	20040929	CN 2004-10032369	19991223
CN 1636988	A	20050713	CN 2004-10086926	19991223
IL 144012	A	20051120	IL 1999-144012	19991223
TW 238155	B	20050821	TW 1999-88122940	19991224
IN 2001MN00483	A	20050617	IN 2001-MN483	20010427
ZA 2001003532	A	20020802	ZA 2001-3532	20010502
HK 1066004	A1	20061020	HK 2004-108874	20041110
IN 2005MN0168	A	20050923	IN 2005-MN168	20050304
IN 2005MN00169	A	20051202	IN 2005-MN169	20050304
PRIORITY APPLN. INFO.: US 1998-114092P P 19981229				
WO 1999-US30748			W	19991223
IN 2001-MN483			A3	20010427

OTHER SOURCE(S): CASREACT 133:89532; MARPAT 133:89532

GI



AB Title ethers [I: R,R1 = (un)substituted Ph] were prepared by epoxidn. of R1CH:CHCH2OH and ring opening of the product by ROH followed by O-protection of the primary hydroxyl, sulfonation of the secondary hydroxyl, deprotection of the primary hydroxyl, ring closure displacing the O-sulfonyl group, and amination of the resulting epoxide.


IT 98769-84-7P, Reboxetine mesylate
RL: SPN (Synthetic preparation); PREP (Preparation)
(process for the preparation of aryl ether diastereomers)

RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT




RN 105017-39-8 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 105017-38-7
CMF C19 H23 N O3

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 1999:514322 CAPLUS
DOCUMENT NUMBER: 131:266516
TITLE: Dose proportionality of reboxetine enantiomers in healthy male volunteers
AUTHOR(S): Rey, E.; Dostert, P.; d'Athis, Ph.; Jannuzzo, M. G.; Poggesi, I.; Olive, G.
CORPORATE SOURCE: Clinical Pharmacology, Hopital Saint-Vincent de Paul, Paris, Fr.
SOURCE: Biopharmaceutics & Drug Disposition (1999), 20(4), 177-181
CODEN: BDDID8; ISSN: 0142-2782

PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Reboxetine is a racemic mixture of FCE 22071 and FCE 21684 enantiomers. The pharmacokinetics of the enantiomers of reboxetine were observed to be linear

in male healthy subjects (n = 6) after the administration of 1.5, 3, 4.5 mg dose of reboxetine as solns. Kinetic anal. was based on chiral HPLC assay of the enantiomers in plasma collected up to 72 h after each administration. Cmax and AUC were more than double for FCE 22071 (Cmax: 38.3±13.5, 76.6±26.3, 99.8±24.1 ng/mL and AUC: 605.8±233.2, 1288.3±796.4, 1780.7±669.3 ng·h/mL for 1.5, 3, 4.5 mg, resp.) than for FCE 21684 (Cmax: 15.2±5.3, 34.6±14.0, 43.1±12.3 ng/mL and AUC: 247.0±103.9, 529.1±278.4, 773.0±355.3 ng·h/mL), whatever the administered dose. The half-lives of the enantiomers were similar (FCE 22071: 13.1, 11.0, 12.6 h and FCE 21684: 12.8, 11.2, 12.2 h after 1.5, 3, 4.5 mg, resp.) and not substantially affected by the dose level.


IT 98819-77-3, FCE 21684 105017-39-8; FCE 22071
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(dose proportionality of reboxetine enantiomers in healthy male volunteers)

RN 98819-77-3 CAPLUS
CN Morpholine, 2-[(S)-(2-ethoxyphenoxy)phenylmethyl]-, (2S)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 98819-76-2
CMF C19 H23 N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 75-75-2

ACCESSION NUMBER: 1997:359492 CAPLUS
DOCUMENT NUMBER: 127:75474
TITLE: Pharmacokinetics of reboxetine enantiomers in the dog
AUTHOR(S): Frigerio, E.; Benecchi, A.; Bianceschi, G.; Pellizzoni, C.; Poggesi, I.; Strolin Benedetti, M.; Dostert, P.
CORPORATE SOURCE: Pharmacokinetics Metabolism Department, Pharmacia & Upjohn, Milan, Italy
SOURCE: Chirality (1997), 9(3), 303-306
CODEN: CHRLEP; ISSN: 0899-0042

PUBLISHER: Wiley-Liss
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Reboxetine, (RS)-2-[(RS)-α-(2-ethoxyphenoxy)benzyl]morpholine methanesulfonate, is a racemic compound and consists of a mixture of the (R,R)- and (S,S)-enantiomers. The pharmacokinetics of reboxetine enantiomers were determined in a crossover study in three male beagle dogs.

Each animal received the following oral treatments, separated by 1-wk washout period: 10 mg/kg reboxetine, 5 mg/kg (R,R)- and 5 mg/kg (S,S)-. Plasma and urinary levels of the reboxetine enantiomers were monitored 548 h post-dosing using an enantiospecific HPLC method with fluorimetric detection (LOQ: 1.1 ng/mL in plasma and 5 ng/mL in urine for each enantiomer). After reboxetine administration, mean tmax was about 1 h for both enantiomers. Cmax and AUC were about 1.5 times higher for the (R,R)- than for the (S,S)-enantiomer, mean values being 704 and 427 ng/mL for Cmax and 2,876,354 and 1,998 ng·h/L for AUC, resp. No differences between the (R,R)- and (S,S)-enantiomers were observed in t1/2 (3.9 h). Total recovery of the two enantiomers in urine was similar, the Ae (0-48 h) being 1.3 and 1.1% of the enantiomer dose for the (R,R)- and the (S,S)-enantiomers, resp. No marked differences in the main plasma pharmacokinetic parameters were found for either enantiomer on administration of the single enantiomers or reboxetine. No chiral inversion was observed after administration of the sep. enantiomers, as already observed in humans.


IT 98769-84-7, FCE 20124 98819-77-3, FCE 21684
105017-39-8, FCE 22071
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmacokinetics of reboxetine enantiomers in dog)

RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.




CM 2
CRN 75-75-2
CMF C H4 O3 S



RN 98819-77-3 CAPLUS
CN Morpholine, 2-[(S)-(2-ethoxyphenoxy)phenylmethyl]-, (2S)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1
CRN 98819-76-2
CMF C19 H23 N O3

Absolute stereochemistry. Rotation (+).



CM 2
CRN 75-75-2
CMF C H4 O3 S




RN 105017-39-8 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1995:716659 CAPLUS
DOCUMENT NUMBER: 123:131950
TITLE: Stereoselective and species-dependent kinetics of reboxetine in mouse and rat
AUTHOR(S): Benedetti, Margherita; Frigerio, Enrico; Tocchetti, Paola; Brianeschi, Gianantonio; Castelli, Maria Grazia; Pellizzoni, Cinzia; Dostert, Philippe
CORPORATE SOURCE: Dep. Pharmacokinetics Metabolism, Pharmacia, Milan, Italy
SOURCE: Chirality (1995), 7(4), 285-9
CODEN: CHRLEP; ISSN: 0899-0042
PUBLISHER: Wiley-Liss
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Reboxetine, (RS)-2-[(RS)-α-(2-ethoxyphenoxy)benzyl]morpholine methanesulfonate, is a racemic compound and consists of a mixture of the (R,R)- and (S,S)-enantiomers. In this study, brain and plasma levels of both enantiomers were determined in mice and rats after oral administration of reboxetine at doses (1.1 mg/kg, mouse; 20 mg/kg, rat) twice the resp. ED50 values in the antiserpine test. Plasma and brain concns. of each enantiomer were measured up to 6 h postdosing using an HPLC method with fluorimetric detection after derivatization with a chiral agent (FLEC). In mice and rats, brain and plasma levels of the (R,R)-enantiomer were always higher than those of the (S,S)-enantiomer. After normalization for dose, the mean AUC0-tz values of both the (R,R)- and (S,S)-enantiomers in mouse brain were about 23 and 32 times higher than in rat brain, resp. In plasma, the corrected mean AUC0-tz values were about 5 (R,R) and 10 (S,S) times higher in mice than in rats. These results provide evidence for the higher bioavailability and/or lower clearance of both enantiomers in mice than in rats, and for a higher penetration of both enantiomers into mouse brain compared to rat brain.
IT 98769-84-7 98819-77-3 105017-39-8
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(reboxetine stereoselective and species-dependent kinetics in mouse and rat)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1
CRN 71620-89-8
CMF C19 H23 N O3

Relative stereochemistry.



methanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 105017-38-7
CMF C19 H23 N O3

Absolute stereochemistry.



CM 2
CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


CM 2
CRN 75-75-2
CMF C H4 O3 S



RN 98819-77-3 CAPLUS
CN Morpholine, 2-[(S)-(2-ethoxyphenoxy)phenylmethyl]-, (2S)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1
CRN 98819-76-2
CMF C19 H23 N O3

Absolute stereochemistry. Rotation (+).




CM 2
CRN 75-75-2
CMF C H4 O3 S



RN 105017-39-8 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1
CRN 105017-38-7
CMF C19 H23 N O3


Absolute stereochemistry.



CM 2
CRN 75-75-2
CMF C H4 O3 S




ACCESSION NUMBER: 1994:235242 CAPLUS
DOCUMENT NUMBER: 120:235242
TITLE: Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed-phase high-performance liquid chromatography with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl)ethyl chloroformate
AUTHOR(S): Frigerio, E.; Planezzola, E.; Strolin Benedetti, M.
CORPORATE SOURCE: Research and Development, Pharmacokinetics and Metabolism Department, Farmitalia Carlo Erba, Nerviano, Milan, 20014, Italy
SOURCE: Journal of Chromatography, A (1994), 660(1-2), 351-8
CODEN: JCRAEY; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A sensitive and selective high-performance liquid chromatog. method for the determination of reboxetine enantiomers in human plasma was developed. Although two chiral centers are present in reboxetine, its stereospecific synthesis leads to two rather than four possible enantiomers. After extraction from plasma and reaction with (+)-1-(9-fluorenyl)ethyl chloroformate, reboxetine enantiomers were separated as diastereoisomeric derivs. by reversed-phase high-performance liquid chromatog. (HPLC) and determined by fluorimetric detection. The HPLC anal. time was about 90 min. The linearity, precision, accuracy and limit of quantification of the method were evaluated. No interference from blank plasma sample was observed. The suitability of the method for in vivo samples was assessed by the anal. of plasma samples obtained from a healthy male volunteer who had received a single oral dose of 4 mg of reboxetine in tablet form.
IT 98769-84-7, FCE 20124
RL: ANST (Analytical study)
(enantiomeric resolution and determination of, in blood plasma of humans by HPLC with fluorimetric detection after derivatization with fluorenyl ethyl chloroformate)
RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 71620-89-8
CMF C19 H23 N O3
Relative stereochemistry.



CM 2
CRN 75-75-2
CMF C H4 O3 S




IT 98819-77-3, FCE 21684 105017-39-8, FCE 22071
RL: ANST (Analytical study)
(resolution and determination of, as reboxetine enantiomer in blood plasma of humans, by HPLC with fluorimetric detection after derivatization with fluorenyl ethyl chloroformate)
RN 98819-77-3 CAPLUS
CN Morpholine, 2-[(S)-(2-ethoxyphenoxy)phenylmethyl]-, (2S)-, methanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 98819-76-2
CMF C19 H23 N O3
Absolute stereochemistry. Rotation (+).



CM 2
CRN 75-75-2
CMF C H4 O3 S



RN 105017-39-8 CAPLUS
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 105017-38-7
CMF C19 H23 N O3
Absolute stereochemistry.



CM 2
CRN 75-75-2
CMF C H4 O3 S



L16 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:187425 CAPLUS

DOCUMENT NUMBER: 116:187425

TITLE: Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man
Cocchiara, G.; Battaglia, R.; Pevarello, P.; Strolin Benedetti, M.


CORPORATE SOURCE: Erbamont Group, Farmitalia Carlo Erba Res. Dev., Milan, I-20159, Italy

SOURCE: European Journal of Drug Metabolism and Pharmacokinetics (1991), 16(3), 231-9
CODEN: EJDPD2; ISSN: 0398-7639

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB The purpose of this study was to compare the disposition and the metabolic pattern of Reboxetine (I) in several species, including man. [14C]I was given orally to the rat, the dog, the monkey (5 mg/kg) and man (2 and 4 mg/kg). Radioactivity was eliminated both by the renal and fecal route

in the rat and the dog, mainly in urine in the monkey and man. I was extensively metabolized. A number of urinary metabolites were quantified by

radio-HPLC and tentatively identified by comparison with the retention times of reference compds. Suggested routes of metabolic transformation are:

2-O-dealkylation; hydroxylation of the ethoxyphenoxy ring; oxidation of the morpholine ring; morphine ring-opening; and combinations of these. Metabolites were partially or completely conjugated with glucuronic acid and/or sulfuric acid.

IT 98769-84-7, Reboxetine mesylate
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(comparative disposition and metabolic pattern of, in laboratory animals and humans)

RN 98769-84-7 CAPLUS
CN Morpholine, 2-[(R)-[2-ethoxyphenoxy]phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 71620-89-8

CMF C19 H23 N O3

L16 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

Relative stereochemistry.

(Continued)



CM 2

CRN 75-75-2

CMF C H4 O3 S



L16 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:471507 CAPLUS

DOCUMENT NUMBER: 115:71507

TITLE: Preparation of 2-[(R)-[2-ethoxyphenoxy]benzyl]-[5-14C]morpholine methanesulfonate ([14C]reboxetine), a new antidepressant agent

AUTHOR(S): Angiulli, Patrizia; Fontana, Ezminia; Vicario, Gian Piero

CORPORATE SOURCE: Metab. Pharmacokinet. Dep., Farmitalia Carlo Erba S.r.l., Milan, 20124, Italy

SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals


(1991), 29(5), 607-11
CODEN: JLCRD4; ISSN: 0362-4803

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 115:71507

GI



I

AB Title compound I was prepared by cyclization of

CH(OH)(CHRR1)CH2NH18COCH2Cl (R = 2-ethoxyphenoxy, R1 = Ph) to give the morpholine which underwent reduction

I was 98% radiochem. pure and has a specific radioactivity of 988 MBq/mmol.

IT 135020-16-5P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 135020-16-5 CAPLUS

CN Morpholine-3-14C, 6-[(2-ethoxyphenoxy)phenylmethyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 135020-15-4

CMF C19 H23 N O3



CM 2

L16 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

CRN 75-75-2

CMF C H4 O3 S

(Continued)



L16 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:591107 CAPLUS
DOCUMENT NUMBER: 105:191107
TITLE: Enantiomers of phenoxy derivatives of

benzylmorpholine

INVENTOR(S): and its salts, and pharmaceuticals containing them
Melloni, Piero; Torre, Arturo Della; Carniel,
Giovanni; Rossi, Alessandro

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Italy

SOURCE: Ger. Offen., 36 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3540093	A1	19860528	DE 1985-3540093	19851112
GB 2167407	A	19860529	GB 1984-29546	19841122
GB 2167407	B	19860511		
JP 61129174	A	19860617	JP 1985-258816	19851120
JP 06067916	B	19940831		
FR 2573425	A1	19860523	FR 1985-17324	19851122
FR 2573425	B1	19881223		
PRIORITY APPLN. INFO.:			GB 1984-29546	A 19841122

OTHER SOURCE(S): CASREACT 105:191107; MARPAT 105:191107

GI



AB 2R,3R- Or 2S,3S-enantiomers of (phenoxybenzyl)morpholines I (R = C1-6 alkoxy, trihalomethyl) and their salts, useful as antidepressants, are prepared. Thus, (+)-(2S,3R)-phenylglycidic acid D(+)-α-methylphenethylamine was reduced with NaBH4 to give (+)2R,3R-cinnamic alc.

2,3-epoxide, which was reacted with 2-ethoxyphenol to give (+)2R,3S-3-(2-ethoxyphenoxy)-1,2-dihydroxy-3-phenylpropane. The diol was reacted with 4-nitrobenzoyl chloride, the product was mesylated and then converted to (-)2S,3S-3-(2-ethoxyphenoxy)-3-phenylpropane-1,2-epoxide, which underwent successively ammonolysis, chloroacetylation, cyclization, and reduction to give (+)2S,3S-2-[α-(2-ethoxyphenoxy)benzyl]morpholine-MeSO3H (II). A tablet was formulated containing II:5, lactose 143,

starch 45, talc 5, and Mg stearate 2 mg.

IT 98819-77-3P 105017-39-8P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as antidepressant)

RN 98819-77-3 CAPLUS

L16 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 98769-84-7

RL: PROC (Process)

(resolution of)

RN 98769-84-7 CAPLUS


CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8

CMF C19 H23 N O3

Relative stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



L16 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Morpholine, 2-[(S)-(2-ethoxyphenoxy)phenylmethyl]-, (2S)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 98819-76-2

CMF C19 H23 N O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 105017-39-8 CAPLUS


CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 105017-38-7

CMF C19 H23 N O3

Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S

L16 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:578207 CAPLUS

DOCUMENT NUMBER: 103:178207

TITLE: Configurational studies on 2-[α-(2-ethoxyphenoxy)benzyl]morpholine PCE 20124

AUTHOR(S): Melloni, P.; Della Torre, A.; Lazzari, E.; Mazzini, G.; Meroni, M.

CORPORATE SOURCE: Ric. Sviluppo Chim., Farm. Carlo Erba S.p.A., Milan, 20159, Italy

SOURCE: Tetrahedron (1985), 41(7), 1393-9


DOCUMENT TYPE: CODEN: TETRAB; ISSN: 0040-4020

LANGUAGE: Journal

OTHER SOURCE(S): English

CASREACT 103:178207

GI



AB The relative configuration of the diastereoisomers of (±)-2-[α-(2-ethoxyphenoxy)benzyl]morpholine (I) is determined by a synthesis involving regio- and stereospecific reactions. (RS,RS)-I was separated into its (+)- and (-)-enantiomers both by crystallization of the optically active mandelate salt

and by a multi-step synthesis from (+)-(2S,3R)-3-phenylglycidic acid.

IT 98769-84-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and resolution of)

RN 98769-84-7 CAPLUS


CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 71620-89-8

CMF C19 H23 N O3

Relative stereochemistry.



CM 2

L16 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 75-75-2
CMF C H4 O3 S




IT 98819-77-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 98819-77-3 CAPLUS
CN Morpholine, 2-[(S)-(2-ethoxyphenoxy)phenylmethyl]-, (2S)-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 98819-76-2
CMF C19 H23 N O3

Absolute stereochemistry. Rotation (+).



CM 2


CRN 75-75-2
CMF C H4 O3 S



L16 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 93851-86-6
CMF C19 H23 N O3



CM 2

CRN 75-75-2
CMF C H4 O3 S




L16 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:24560 CAPLUS
DOCUMENT NUMBER: 102:24560

TITLE: Potential antidepressant agents. α -Aryloxybenzyl derivatives of ethanolamine and morpholine
Melloni, Piero; Carniel, Giovanni; Della Torre, Arturo; Bonsignori, Alberto; Buonamici, Matilde; Pozzi, Ottorino; Ricciardi, Sante; Rossi, Alessandro C.

CORPORATE SOURCE: Farmitalia C. Erba S.p.A., Milan, 20159, Italy
SOURCE: European Journal of Medicinal Chemistry (1984), 19(3),

235-42
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 102:24560
GI



AB The title compds. I and II (R = Me, H, Cl, MeO, methylenedioxy; R1 = H, Me, R2 = H, MeO, Cl; R3 = H, Me, Me2CH; R4, R5 = H, Me; R6 = H, Me, Ac, MeNHCO, etc.; X = O, CH2, MeN) were prepared as antidepressants from phenoxyacetates III (R7 = Et). Thus, III (R = 2-MeO, R1 = R2 = R7 = H) was treated with carbonyldiimidazole and nitromethane sodium salt to give the nitro enolate, which was reduced by H2/PtO2 to give 2 diastereoisomers

of I (R = 2-MeO, R1-R5 H). II (R = 2-EtO, R1 = R2 = R6 = H; X = O) showed

outstanding activity in the antiserpine test when compared with Imipramine, Desipramine and Viloxazine.

IT 93851-87-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antidepressant activity of)

RN 93851-87-7 CAPLUS

CN Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, methanesulfonate (9CI) (CA INDEX NAME)

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

225.10

SINCE FILE

ENTRY

-32.76

TOTAL

SESSION

607.75

TOTAL

SESSION

-33.54

STN INTERNATIONAL LOGOFF AT 08:28:17 ON 13 MAR 2007